

## TOTAL PRODUCTION

Nom de l'équipe :	Inflammation, Complement and Cancer
Nom du directeur pour le contrat en cours :	Isabelle CREMER et Jean-Luc TEILLAUD
Nom de l'équipe :	Complement and diseases
Nom du directeur pour le contrat en cours :	Veronique FREMEAUX-BACCHI
Nom de l'équipe pour le contrat à venir :	Inflammation, complement and cancer
Nom du directeur pour le contrat à venir :	Isabelle CREMER

*Publications made in collaboration with other teams of the CRC are flagged with ■*

*Publications of staff recruited during the last five years and done in their previous team are flagged with ➡*

### I. PRODUITS DE LA RECHERCHE

#### 1. Journaux / revues

##### Articles scientifiques

##### Bibliometric analysis

*The total scientific production of the teams Cremer/ Teillaud and Fremeaux-Bacchi for the period 2012-May 2017 consist 335 publications. Of these, 200 are original articles (published in 100 different journals), 135 are reviews.*

*Among the 200 original articles, 122 (61%) are from the team Cremer/ Teillaud and 78 (39%) are from the team Fremeaux-Bacchi. 15% are in journals with IF above 10 and 40% are between IF5 and IF10. From the publications of Cremer/ Teillaud team, 17% are above IF10 and 33% are between IF10 and IF5. From the production of the team Fremeaux-Bacchi, 10% are with IF above 10 and 50% are between IF10 and IF5. 21 papers are collaborations with different labs in the center, mainly with the teams of Kroemer, Lacroix-Desmazes and Galon from Department 2, but also with the ones of Edwards/Houillier and Leturque from Department 1 and the CICC platform of CRC.*

*Among the 135 reviews, 71% are from the team of Cremer/ Teillaud and 29% are from the team of Fremeaux-Bacchi. Total of 67 reviews are in collaboration with other teams of the center, including Cremer/ Teillaud, Kroemer, Galon and Lacroix-Desmazes. Notable are 46 reviews in Oncoimmunol, which are in its large majority collaborative effort of three teams of the center, namely Cremer/ Teillaud, Kroemer and Galon, published with the support of the European Academy of Tumor Immunology. 3 reviews of the team Fremeaux-Bacchi are in collaboration with the team of Lacroix-Desmazes.*

*In addition, there are 7 books and 25 book chapters for the two teams.*

##### Original articles

#### 2017 – Team Cremer/ Teillaud

1. Giraldo NA, Becht E, Vano Y, Petitprez F, Lacroix L, Validire P, Sanchez-Salas R, Ingels A, Oudard S, Moatti A, Buttard B, Bourass S, Germain C, Cathelineau X, Fridman WH, Sautès-Fridman C. (2017) Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. *Clin Cancer Res.* Feb 17. PMID:28213366
2. ■ Fend L, Rusakiewicz S, Adam J, Bastien B, Caignard A, Messaoudene M, Iribarren C, Cremer I, Marabelle A, Borg C, Semeraro M, Barraud L, Limacher JM, Eggermont A, Kroemer G, Zitvogel L. (2017) Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. *Oncoimmunology.* 2016 May 13;6(1):e1163456. eCollection 2017. PMID:28197362
3. Laurent C, Baron M, Amara N, Haioun C, Dandoit M, Maynadié M, Parrens M, Vergier B, Copie-Bergman C, Fabiani B, Traverse-Glehen A, Brousse N, Copin MC, Tas P, Petrella T, Rousselet MC, Brière J, Charlotte F, Chassagne-Clement C, Rousset T, Xerri L, Moreau A, Martin A, Damotte D, Dartigues P, Soubeyran I, Peoch M, Dechelotte P, Michiels JF, de Mascarel A, Berger F, Bossard C, Arbion F, Quintin-Roué I, Picqueton JM, Patey M, Fabre B, Sevestre H, Le Naoures C, Chenard-Neu MP, Bastien C, Thiebault S, Martin L, Delage M, Filleron T, Salles G, Molina TJ, Delsol G, Brousset P, Gaulard P. (2017) Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. *J Clin Oncol.* May 1:JCO2016712083. PMID:28459613
4. Frija-Masson J, Martin C, Regard L, Lothe MN, Touqui L, Durand A, Lucas B, Damotte D, Alifano M, Fajac I, Burgel PR. (2017) Bacteria-driven peribronchial lymphoid neogenesis in bronchiectasis and cystic fibrosis. *Eur Respir J.* Apr 26;49(4). PMID:28446556
5. Zhou Z, Xu L, Sennepin A, Federici C, Ganor Y, Tudor D, Damotte D, Barry Delongchamps N, Zerbib M, Bomsel M. (2017) The HIV-1 viral synapse signals human foreskin keratinocytes to secrete thymic stromal lymphopoietin facilitating HIV-1 foreskin entry. *Mucosal Immunol.* Apr 26. PMID:28443609
6. Gravelle P, Burroni B, Péricart S, Rossi C, Bezombes C, Tosolini M, Damotte D, Brousset P, Fournié JJ, Laurent C. (2017) Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. *Oncotarget.* Mar 29. Review. PMID: 28402953
7. Le Goux C, Damotte D, Vacher S, Sibony M, Delongchamps NB, Schnitzler A, Terris B, Zerbib M, Bieche I, Pignot G. (2017) Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study. *Urol Oncol.* May;35(5):257-263. PMID:28291636
8. Fournel L, Etienne H, Mansuet Lupo A, Damotte D, Rouquette A, Revel MP, Guinet C, Alifano M, Regnard JF. (2017) Correlation between radiological and pathological features of operated ground glass nodules. *Eur J Cardiothorac Surg.* Feb 1;51(2):248-254. PMID:28186249
9. Sarkozy C, Molina T, Ghesquières H, Michallet AS, Dupuis J, Damotte D, Morsschauser F, Parrens M, Martin L, Dartigues P, Stamatoullas A, Hirsch P, Fabiani B, Bouabdallah K, da Silva MG, Maerevoet M, Laurent C, Coiffier B, Salles G, Traverse-Glehen A. (2017) Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. *Haematologica.* Jan;102(1):150-159. PMID: 27758822
10. Hervochon R, Bobbio A, Guinet C, Mansuet-Lupo A, Rabbat A, Régnard JF, Roche N, Damotte D, Iannelli A, Alifano M. (2017) Body Mass Index and Total Psoas Area Affect Outcomes in Patients Undergoing Pneumonectomy for Cancer. *Ann Thorac Surg.* Jan;103(1):287-295. PMID: 27659598
11. Petitprez, Fossati, Vano, Freschi, Becht, Lucianò, Calderaro, Guédet, Lacroix, Rancoita, Montorsi, Fridman, Sautès-Fridman, Briganti, Doglioni, Bellone PD-L1 Expression and CD8+ T cell Infiltrate are Associated with Clinical Progression in Patients with Node Positive Prostate Cancer. *Eur Urol Focus*, 2017, in press

**2017 - Team Fremeaux-Bacchi**

12. Marinozzi MC., Chauvet S., Le Quintrec, M., Mignotet, M., Legendre, C., Cailliez, M., Deschenes, D., Fischbach, F., Karras A., Nobili F., Pietrement C., Dragon-Durey MA., Fakhouri F., Roumenina LT. and Veronique Fremeaux-Bacchi. (2017) C5 Nephritic Factors drive the biological phenotype of C3 Glomerulopathies, *Kidney international*, in press
13. Togarsimalemath, SK., Sethi, SK., Duggal, R., Le Quintrec, M., Jha, P., Daniel R., Gonnet, F., Bansal, S., Roumenina, LT., Fremeaux-Bacchi, V., Kher, V., and Dragon-Durey, MA. (2017) A novel CFHR1-CFHR5 hybrid leading to a familial dominant C3 Glomerulopathy, *Kidney international*, in press
14. Marinozzi, M. C., Roumenina, L. T., Chauvet, S., Hertig, A., Bertrand, D., Olagne, J., Frimat, M., Ulinski, T., Deschenes, G., Burtey, S., Delahousse, M., Moulin, B., Legendre, C., Fremeaux-Bacchi, V., and Le Quintrec, M. (2017) Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN, *Journal of the American Society of Nephrology : JASN* 28, 1603-1613.
15. Chauvet, S., Fremeaux-Bacchi, V., Petitprez, F., Karras, A., Daniel, L., Burtey, S., Choukroun, G., Delmas, Y., Guerrot, D., Francois, A., Le Quintrec, M., Javaugue, V., Ribes, D., Vrigneaud, L., Arnulf, B., Goujon, J. M., Ronco, P., Touchard, G., and Bridoux, F. (2017) Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy, *Blood* 129, 1437-1447.

16. Pedersen, D. V., Roumenina, L., Jensen, R. K., Gadeberg, T. A., Marinozzi, C., Picard, C., Rybkine, T., Thiel, S., Sorensen, U. B., Stover, C., Fremeaux-Bacchi, V., and Andersen, G. R. (2017) Functional and structural insight into properdin control of complement alternative pathway amplification, *The EMBO journal* 36, 1084-1099.
17. ■ Djoumerska-Alexieva, I., Roumenina, L. T., Stefanova, T., Vassilev, T., and Dimitrov, J. D. (2017) Heme-Exposed Pooled Therapeutic IgG Improves Endotoxemia Survival, *Inflammation* 40, 117-122.
18. Rosain, J., Hong, E., Fieschi, C., Vieira Martins, P., El Sissy, C., Deghmane, A. E., Ouachee, M., Thomas, C., Launay, D., de Pontual, L., Suarez, F., Moshous, D., Picard, C., Taha, M. K., and Fremeaux-Bacchi, V. (2017) Strains responsible for invasive meningococcal disease in patients with terminal complement pathway deficiencies, *The Journal of infectious diseases*.
19. Azukaitis, K., Simkova, E., Majid, M. A., Galiano, M., Benz, K., Amann, K., Bockmeyer, C., Gajjar, R., Meyers, K. E., Cheong, H. I., Lange-Sperandio, B., Junggraithmayr, T., Fremeaux-Bacchi, V., Bergmann, C., Bereczki, C., Miklaszewska, M., Csuka, D., Prohaszka, Z., Gipson, P., Sampson, M. G., Lemaire, M., and Schaefer, F. (2017) The Phenotypic Spectrum of Nephropathies Associated with Mutations in Diacylglycerol Kinase epsilon, *Journal of the American Society of Nephrology : JASN*.
20. Brackman, D., Sartz, L., Leh, S., Kristoffersson, A. C., Bjerre, A., Tati, R., Fremeaux-Bacchi, V., and Karpman, D. (2017) Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis, *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association* 32, 584.
21. Fakhouri, F., Fila, M., Provot, F., Delmas, Y., Barbet, C., Chatelet, V., Rafat, C., Cailliez, M., Hogan, J., Servais, A., Karras, A., Makdassi, R., Louillet, F., Coindre, J. P., Rondeau, E., Loirat, C., and Fremeaux-Bacchi, V. (2017) Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation, *Clinical journal of the American Society of Nephrology : CJASN* 12, 50-59.
22. Lebreton, C., Bacchetta, J., Dijoud, F., Bessenay, L., Fremeaux-Bacchi, V., and Sellier-Leclerc, A. L. (2017) C3 glomerulopathy and eculizumab: a report on four paediatric cases, *Pediatric nephrology* 32, 1023-1028.
23. Raghunathan, V., Sethi, S. K., Dragon-Durey, M. A., Dhaliwal, M., Raina, R., Jha, P., Bansal, S. B., and Kher, V. (2017) Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome, *Indian journal of nephrology* 27, 136-140.
24. Sanges, S., Wallet, F., Blondiaux, N., Theis, D., Verin, I., Vachee, A., Dessein, R., Faure, K., Viget, N., Senneville, E., Leroy, O., Maury, F., Just, N., Poissy, J., Mathieu, D., Prevot, A., Chenivresse, C., Scherpereel, A., Smith, G., Lopez, B., Rosain, J., Fremeaux-Bacchi, V., Hachulla, E., Hatron, P. Y., Bahuaud, M., Batteux, F., Launay, D., Labalette, M., and Lefevre, G. (2017) Diagnosis of primary antibody and complement deficiencies in young adults after a first invasive bacterial infection, *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*.
25. Sethi, S. K., Rohatgi, S., Dragon-Durey, M. A., Raghunathan, V., Dhaliwal, M., Rawat, A., Jha, P., Bansal, S. B., Raina, R., and Kher, V. (2017) Eculizumab for atypical hemolytic-uremic syndrome in India: First report from India and the challenges faced, *Indian journal of nephrology* 27, 58-61.

#### 2016 - Team Cremer/ Teillaud

26. Mansuet-Lupo A, Alifano M, Pécuchet N, Biton J, Becht E, Goc J, Germain C, Ouakrim H, Régnard JF, Cremer I, Laurent-Puig P, Dieu-Nosjean MC, Blons H, Damotte D. (2016) Intra-tumoral Immune Cell Densities are Associated with Lung Adenocarcinoma Gene Alterations. *Am J Respir Crit Care Med*. Jun 14. PMID: 27299180. IF=13.1
27. Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman C, Fridman WH, de Reyniès A. (2016) Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. *Genome Biol*. 17(1):218. PMID: 27765066.
28. Becht E, de Reyniès A, Giraldo NA, Pilati C, Buttard B, Lacroix L, Selves J, Sautès-Fridman C, Laurent-Puig P, Fridman WH. (2016) Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. *Clin Cancer Res*. pii: clincanres.2879. PMID: 26994146. IF=8.7
29. Remark R, Lupo A, Alifano M, Biton J, Ouakrim H, Stefani A, Cremer I, Goc J, Régnard JF, Dieu-Nosjean MC, Damotte D. (2016) Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients. *Oncoimmunology*. Dec 8;5(12):e1255394. eCollection 2016. PMID: 28123901
30. Cosette J, Ben Abdelwahed R, Donnou-Triffault S, Sautès-Fridman C, Flaud P, Fisson S. (2016) Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects

in Mouse Lymphoma Models. *J Vis Exp.* Jul 7;(113). PMID: 27501019

31. Just PA, Verkarre V, **Mansuet-Lupo A**, Rabant M, Daniliuc C, Radenen B, Harent M, Cassanelli L, Cherel É, Javaux H, Tesniere A, Terris B, Badoual C. (2016) [Innovations in medical undergraduate pathology education: The Paris Descartes medicine faculty experience]. *Ann Pathol.* 36:252-7. PMID: 27475003.

32. Gaucher S, Bobbio A, **Mansuet-Lupo A**, Hamelin-Canny E, Hautier A, Nicolas C, Alifano M. (2016) Late costal osteomyelitis with a cutaneous fistula after flame burns: a case report. *J Wound Care.* 25:104, 106-7. PMID: 26878303.

33. Hélége S, Revel MP, Chabi ML, Audureau É, Ferretti G, Laurent F, Alifano M, **Mansuet-Lupo A**, Buy JN, Vadrot D. (2016) Solitary fibrous tumor of the pleura: Can computed tomography features help predict malignancy? A series of 56 patients with histopathological correlates. *Diagn Interv Imaging.* 97:347-53. PMID: 26542536.

34. Jardin F, Pujals A, Pelletier L, Bohers E, Camus V, Mareschal S, Dubois S, Sola B, Ochmann M, Lemonnier F, Viailly PJ, Bertrand P, Maingonnat C, Traverse-Glehen A, Gaulard P, **Damotte D**, Delarue R, Haioun C, Argueta C, Landesman Y, Salles G, Jais JP, Figeac M, Copie-Bergman C, Molina TJ, Picquenot JM, Cornic M, Fest T, Milpied N, Lemasle E, Stamatoullas A, Moeller P, Dyer MJ, Sundstrom C, Bastard C, Tilly H, Leroy K. (2016) Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. *Am J Hematol.* 91:923-30. PMID: 27312795.

35. ■ Fucikova J, Truxova I, Hensler M, Becht E, Kasikova L, Moserova I, Vosahlikova S, Klouckova J, Church SE, **Cremer I**, Kepp O, Kroemer G, Galluzzi L, Salek C, Spisek R. (2016) Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. *Blood.* 128:3113-3124. PMID: 27802968.

36. ■ Stoll G, Iribarren K, Michels J, Leary A, Zitvogel L, **Cremer I**, Kroemer G. (2016) Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer. *Oncoimmunology.* 5(7):e1177692. PMID: 27622029.

37. Hervier B, **Perez M**, Allenbach Y, Devilliers H, Cohen F, Uzunhan Y, **Ouakrim H**, Dorgham K, Méritet JF, Longchamp E, Stenzel W, **Cremer I**, Benveniste O, Vieillard V. (2016) Involvement of NK Cells and NKp30 Pathway in Antisynthetase Syndrome. *J Immunol.* 197:1621-30. PMID: 27511738. IF=4.9

38. Gourdy P, Bourgeois EA, Levescot A, Pham L, Riant E, Ahui ML, **Damotte D**, Gombert JM, Bayard F, Ohlsson C, Arnal JF, Herbelin A. (2016) Estrogen Therapy Delays Autoimmune Diabetes and Promotes the Protective Efficiency of Natural Killer T-Cell Activation in Female Nonobese Diabetic Mice. *Endocrinology.* 157:258-67. PMID: 26485613

39. 📧 Decque A, Joffre O, Magalhaes JG, Cossec JC, Blecher-Gonen R, Lapaquette P, Silvin A, Manel N, **Joubert PE**, Seeler JS, Albert ML, Amit I, Amigorena S, Dejean A. (2016) Sumoylation coordinates the repression of inflammatory and anti-viral gene-expression programs during innate sensing. *Nat Immunol.* 17:140-9. PMID: 26657003

#### 2016 - Fremeaux-Bacchi

40. Chauvet, S., Roumenina, L. T., Bruneau, S., Marinozzi, M. C., Rybkine, T., Schramm, E. C., Java, A., Atkinson, J. P., Aldigier, J. C., Bridoux, F., Touchard, G., and Fremeaux-Bacchi, V. (2016) A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H, *Journal of the American Society of Nephrology : JASN* 27, 1665-1677.1.

41. Audemard-Verger, A., Descloux, E., Ponard, D., Deroux, A., Fantin, B., Fieschi, C., John, M., Bouldouyre, A., Karkowski, L., Moulis, G., Auvinet, H., Valla, F., Lechiche, C., Davido, B., Martinot, M., Biron, C., Lucht, F., Asseray, N., Froissart, A., Buzele, R., Perlat, A., Boutboul, D., **Fremeaux-Bacchi, V.**, Isnard, S., and Bienvenu, B. (2016) Infections Revealing Complement Deficiency in Adults: A French Nationwide Study Enrolling 41 Patients, *Medicine* 95, e3548.

42. Caillaud, C., Zaloszyk, A., Licht, C., Pichault, V., **Fremeaux-Bacchi, V.**, and Fischbach, M. (2016) CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS), *Pediatric nephrology* 31, 157-161.

43. Chehade, H., Rotman, S., **Fremeaux-Bacchi, V.**, Aubert, V., Sadallah, S., Sifaki, L., Salomon, R., and Pascual, M. (2016) Blockade of C5 in Severe Acute Postinfectious Glomerulonephritis Associated With Anti-Factor H Autoantibody, *American journal of kidney diseases : the official journal of the National Kidney Foundation* 68, 944-948.

44. Commereuc, M., Weill, F. X., Loukiadis, E., Gouali, M., Gleizal, A., Kormann, R., Ridet, C., **Fremeaux-Bacchi, V.**, Rondeau, E., and Hertig, A. (2016) Recurrent Hemolytic and Uremic Syndrome Induced by Escherichia Coli, *Medicine* 95, e2050.

45. Dumas, G., Habibi, A., Onimus, T., Merle, J. C., Razazi, K., Mekontso Dessap, A., Galacteros, F., Michel, M., Fremeaux Bacchi, V., Noizat Pirenne, F., and Bartolucci, P. (2016) Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients, *Blood* 127, 1062-1064.
46. Gobert, D., Paule, R., Ponard, D., Levy, P., Fremeaux-Bacchi, V., Bouillet, L., Boccon-Gibod, I., Drouet, C., Gayet, S., Launay, D., Martin, L., Mekinian, A., Leblond, V., and Fain, O. (2016) A nationwide study of acquired C1-inhibitor deficiency in France: Characteristics and treatment responses in 92 patients, *Medicine* 95, e4363.
47. Gonzales, E., Ulinski, T., Habes, D., Deschenes, G., Fremeaux-Bacchi, V., and Bensman, A. (2016) Long-term successful liver-kidney transplantation in a child with atypical hemolytic uremic syndrome caused by homozygous factor H deficiency, *Pediatric nephrology* 31, 2375-2378.
48. Iatropoulos, P., Noris, M., Mele, C., Piras, R., Valoti, E., Bresin, E., Curreri, M., Mondo, E., Zito, A., Gamba, S., Bettoni, S., Murer, L., Fremeaux-Bacchi, V., Vivarelli, M., Emma, F., Daina, E., and Remuzzi, G. (2016) Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome, *Molecular immunology* 71, 131-142.
49. Kolm, R., Schaller, M., Roumenina, L. T., Niemiec, I., Kremer Hovinga, J. A., Khanicheh, E., Kaufmann, B. A., Hopfer, H., and Trendelenburg, M. (2016) Von Willebrand Factor Interacts with Surface-Bound C1q and Induces Platelet Rolling, *Journal of immunology* 197, 3669-3679.
50. Servais, A., Devillard, N., Fremeaux-Bacchi, V., Hummel, A., Salomon, L., Contin-Bordes, C., Gomer, H., Legendre, C., and Delmas, Y. (2016) Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab, *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association* 31, 2122-2130.
51. Siomou, E., Gkoutias, A., Serbis, A., Kollios, K., Chaliasos, N., and Fremeaux-Bacchi, V. (2016) aHUS associated with C3 gene mutation: a case with numerous relapses and favorable 20-year outcome, *Pediatric nephrology* 31, 513-517.

#### 2015 - Team Cremer/ Teillaud

52. Remark R, Becker C, Gomez JE, Damotte D, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH, Powell CA, Altorki NK, Merad M, Gnjatic S. (2015). The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. *Am J Respir Crit Care Med.* 191:377-90. PMID: 25369536
53. Deligne C, Metidji A, Fridman WH, Teillaud JL. (2015). Anti-CD20 therapy induces a memory Th1 response through the IFN- $\gamma$ /IL-12 axis and prevents protumor regulatory T-cell expansion in mice. *Leukemia.* 2015 Apr;29(4):947-57. PMID: 25231744
54. Metidji A, Rieder SA, Glass DD, Cremer I, Punkosdy GA, Shevach EM. (2015). IFN- $\alpha$ /B Receptor Signaling Promotes Regulatory T Cell Development and Function under Stress Conditions. *J Immunol.* 194:4265-76. PMID: 25795758
55. Devèvre EF, Renovato-Martins M, Clément K, Sautès-Fridman C, Cremer I, Poitou C. (2015). Profiling of the three circulating monocyte subpopulations in human obesity. *J Immunol.* 194:3917-23. PMID: 25786686
56. Giraldo N, Becht E, Pagès F, Skliris GP, Verkarre V, Vano Y, Mejean A, Saint-Aubert N, Lacroix L, Natario I, Lupo A, Alifano M, Damotte D, Cazes A, Triebel F, Freeman GJ, Dieu-Nosjean MC, Oudard SM, Fridman WH, Sautès-Fridman C. (2015). Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. *Clin Cancer Res.* 21:3031-40. PMID: 25688160
57. Beuselinck B, Job S, Becht E, Karadimou A, Verkarre V, Couchy G, Giraldo N, Rioux-Leclercq N, Molinié V, Sibony M, Elaidi R, Teghom C, Patard JJ, Méjean A, Fridman WH, Sautès-Fridman C, de Reyniès A, Oudard S, Zucman-Rossi J. (2015). Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. *Clin Cancer Res.* 21:1329-39. PMID: 25583177
58. Ben Abdelwahed Bagga R, Donnou S, Cosette J, Sautès-Fridman C, Aouni M, Fisson S. (2015). Mouse models of primary central nervous system lymphomas: tools for basing funding and therapeutic strategies. *J Neurooncol.* 121:9-18. PMID: 25300908
59. Figeac F, Dagouassat M, Mahrouf-Yorgov M, Le Gouvello S, Trébeau C, Sayed A, Stern JB, Validire P, Dubois-Randé JL, Boczkowski J, Mus-Veteau I, Rodriguez AM. (2015). Lung Fibroblasts Share Mesenchymal Stem Cell Features Which Are Altered in Chronic Obstructive Pulmonary Disease via the Overactivation of the Hedgehog Signaling Pathway. *PLoS One.* 2015 Mar 27;10(3):e0121579. PMID: 25815884
60. Mourra N, Cortez A, Bennis M, Guettier C, Zaatari G, Duvillard P, Validire P, Balaton A. (2015). The groin: an unusual location of endometriosis-a multi-institutional clinicopathological study. *J Clin Pathol.* 2015 Mar 18. pii: jclinpath-2014-202812. PMID: 25788452

61. Djenidi F, Adam J, Goubar A, Durgeau A, Meurice G, de Montpréville V, **Validire P**, Besse B, Mami-Chouaib F. (2015). CD8+CD103+ Tumor-Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients. *J Immunol.* 194:3475-86. PMID: 25725111
62. Schwaederlé M, Lazar V, **Validire P**, Hansson J, Lacroix L, Soria JC, Pawitan Y, Kurzrock R. (2015). VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy. *Cancer Res.* 75:1187-90. PMID: 25672981
63. Messaoudene M, Périer A, Fregni G, Neves E, Zitvogel L, **Cremer I**, Chanal J, Sastre-Garau X, Deschamps L, Marinho E, Larousserie F, Maubec E, Avril MF, Caignard A. (2015) Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients. *PLoS One.* 10(7):e0133363. PMID: 26218530
64. ■ Michels J, Adam J, Goubar A, Obrist F, **Damotte D**, Robin A, Alifano M, Vitale I, Olaussen KA, Girard P, **Cremer I**, Castedo M, Soria JC, Kroemer G. (2015) Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer. *Ann Oncol.* 26:2470-7. PMID: 26387143
65. Pécuchet N, Laurent-Puig P, **Mansuet-Lupo A**, Legras A, Alifano M, Pallier K, Didelot A, Gibault L, Danel C, Just PA, Riquet M, Le Pimpec-Barthes F, **Damotte D**, Fabre E, Blons H. (2015) Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer. *Oncotarget.* Nov 25. PMID: 26625312
66. Bougherara H, **Mansuet-Lupo A**, Alifano M, Ngô C, **Damotte D**, Le Frère-Belda MA, Donnadiou E, Peranzoni E. (2015) Real-Time Imaging of Resident T Cells in Human Lung and Ovarian Carcinomas Reveals How Different Tumor Microenvironments Control T Lymphocyte Migration. *Front Immunol.* 6:500. PMID: 26528284
67. Grigoriou M, Tagett R, Draghici S, Dima S, Nastase A, Florea R, Sorop A, Ilie V, Bacalbasa N, Tica V, Laszlo V, **Mansuet-Lupo A**, **Damotte D**, Klepetko W, Popescu I, Regnard JF. (2015) Gene-expression Profiling in Non-small Cell Lung Cancer with Invasion of Mediastinal Lymph Nodes for Prognosis Evaluation. *Cancer Genomics Proteomics.* 12:231-42. PMID: 26417026
68. Janet-Vendroux A, Loi M, Bobbio A, Lococo F, **Lupo A**, Ledinet P, Magdeleinat P, Roche N, **Damotte D**, Regnard JF, Alifano M. (2015) Which is the Role of Pneumonectomy in the Era of Parenchymal-Sparing Procedures? Early/Long-Term Survival and Functional Results of a Single-Center Experience. *Lung.* 193:965-73. PMID: 26411589
69. Bousquet G, El Bouchtaoui M, Leboeuf C, Battistella M, Varna M, Ferreira I, Plassa LF, Hamdan D, Bertheau P, Feugeas JP, **Damotte D**, Janin A. (2015) Tracking sub-clonal TP53 mutated tumor cells in human metastatic renal cell carcinoma. *Oncotarget.* 6:19279-89. PMID: 26002555
70. Bobbio A, Dechartres A, Bouam S, **Damotte D**, Rabbat A, Régnard JF, Roche N, Alifano M. (2015) Epidemiology of spontaneous pneumothorax: gender-related differences. *Thorax.* 70:653-8. PMID: 25918121
71. ■ Monteiro-Sepulveda M, Touch S, Mendes-Sá C, André S, Poitou C, Allatif O, Cotillard A, Fohrer-Ting H, Hubert EL, **Remark R**, Genser L, Tordjman J, Garbin K, Osinski C, **Sautès-Fridman C**, Leturque A, Clément K, Brot-Laroche E. (2015) Jejunal T Cell Inflammation in Human Obesity Correlates with Decreased Enterocyte Insulin Signaling. *Cell Metab.* 22:113-24. PMID: 26094890
72. **Becht E**, de Reyniès A, **Fridman WH**. (2015) Integrating tumor microenvironment with cancer molecular classifications. *Genome Med.* 7:115. PMID: 26568192
73. ■ Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, **Fridman WH**, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Middendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC. (2015) Consensus nomenclature for CD8<sub>T</sub> cell phenotypes in cancer. *Oncoimmunology.* 4:e998538.
74. 📧 **Joubert PE**, Stapleford K, Guivel-Benhassine F, Vignuzzi M, Schwartz O, Albert ML. (2015) Inhibition of mTORC1 Enhances the Translation of Chikungunya Proteins via the Activation of the MnK/eIF4E Pathway. *PLoS Pathog.* 11:e1005091. PMID: 26317997

#### 2015 - Fremeaux-Bacchi

75. Schramm, EC, Roumenina, LT, Rybkine, T, Chauvet, S, Vieira-Martins, P, Hue, C, Maga, T, Valoti, E, Wilson, V, Jokiranta, S, Smith, RJ, Noris, M, Goodship, T, Atkinson, JP, **Fremaux-Bacchi, V**: Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. *Blood*, 125: 2359-2369, 2015.
76. Blanc, C, Togarsimalemath, SK, Chauvet, S, Le Quintrec, M, Moulin, B, Buchler, M, Jokiranta, TS, Roumenina, LT, **Fremaux-Bacchi, V**, **Dragon-Durey, MA**: Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. *Journal of immunology*, 194: 5129-5138, 2015.
77. ■ **Vasilev, VV**, **Noe, R**, **Dragon-Durey, MA**, **Chauvet, S**, Lazarov, VJ, Deliyska, BP, **Fremaux-Bacchi, V**, **Dimitrov, JD**, **Roumenina, LT**: Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis. *The Journal of biological chemistry*, 290: 25343-25355, 2015.

78. Bruneau, S, Neel, M, Roumenina, LT, Frimat, M, Laurent, L, Fremeaux-Bacchi, V, Fakhouri, F: Loss of DGKepsilon induces endothelial cell activation and death independently of complement activation. *Blood*, 125: 1038-1046, 2015.
79. ■ Djoumerska-Alexieva, I, Roumenina, L, Pashov, A, Dimitrov, J, Hadzhieva, M, Lindig, S, Voynova, E, Dimitrova, P, Ivanovska, N, Bockmeyer, C, Stefanova, Z, Fitting, C, Blass, M, Claus, R, Von Gunten, S, Kaveri, S, Cavaillon, JM, Bauer, M, Vassilev, T: Intravenous Immunoglobulin with Enhanced Polyspecificity Improves Survival in Experimental Sepsis and Aseptic Systemic Inflammatory Response Syndromes. *Molecular medicine*, 2015.
80. ■ Hadzhieva, M, Vassilev, TL, Roumenina, LT, Bayry, J, Kaveri, SV, Lacroix-Desmazes, S, Dimitrov, JD: Mechanism and functional implications of the heme-induced binding promiscuity of IgE. *Biochemistry*, 54: 2061-2072, 2015.
81. Jachiet, M, Flageul, B, Deroux, A, Le Quellec, A, Maurier, F, Cordoliani, F, Godmer, P, Abasq, C, Astudillo, L, Belenotti, P, Bessis, D, Bigot, A, Doutre, MS, Ebbo, M, Guichard, I, Hachulla, E, Heron, E, Jeudy, G, Jourde-Chiche, N, Jullien, D, Lavigne, C, Machet, L, Macher, MA, Martel, C, Melboucy-Belkhir, S, Morice, C, Petit, A, Simorre, B, Zenone, T, Bouillet, L, Bagot, M, Fremeaux-Bacchi, V, Guillevin, L, Mouthon, L, Dupin, N, Aractingi, S, Terrier, B, French Vasculitis Study, G: The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. *Arthritis & rheumatology*, 67: 527-534, 2015.
82. Khandelwal, P, Gupta, A, Sinha, A, Saini, S, Hari, P, Dragon Durey, MA, Bagga, A: Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome. *Pediatric nephrology*, 30: 451-457, 2015.
83. Le Quintrec, M, Lionet, A, Kandel, C, Bourdon, F, Gnemmi, V, Colombat, M, Goujon, JM, Fremeaux-Bacchi, V, Fakhouri, F: Eculizumab for treatment of rapidly progressive C3 glomerulopathy. *American journal of kidney diseases : the official journal of the National Kidney Foundation*, 65: 484-489, 2015.
84. Licht, C, Ardissino, G, Ariceta, G, Cohen, D, Cole, JA, Gasteyger, C, Greenbaum, LA, Johnson, S, Ogawa, M, Schaefer, F, Vande Walle, J, Fremeaux-Bacchi, V: The global aHUS registry: methodology and initial patient characteristics. *BMC nephrology*, 16: 207, 2015.
85. Mele, C, Lemaire, M, Iatropoulos, P, Piras, R, Bresin, E, Bettoni, S, Bick, D, Helbling, D, Veith, R, Valoti, E, Donadelli, R, Murer, L, Neunhauserer, M, Breno, M, Fremeaux-Bacchi, V, Lifton, R, Remuzzi, G, Noris, M: Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome. *Clinical journal of the American Society of Nephrology : CJASN*, 10: 1011-1019, 2015.
86. Nester, CM, Barbour, T, de Cordoba, SR, Dragon-Durey, MA, Fremeaux-Bacchi, V, Goodship, TH, Kavanagh, D, Noris, M, Pickering, M, Sanchez-Corral, P, Skerka, C, Zipfel, P, Smith, RJ: Atypical aHUS: State of the art. *Molecular immunology*, 67: 31-42, 2015.
87. Niel, O, Dallochio, A, Thouret, MC, Guignonis, V, Cassuto, E, Fremeaux-Bacchi, V, Berard, E: C3 nephritic factor can be associated with membranous glomerulonephritis. *Pediatric nephrology*, 30: 353-355, 2015.
88. Payette, A, Patey, N, Dragon-Durey, MA, Fremeaux-Bacchi, V, Le Deist, F, Lapeyraque, AL: A case of C3 glomerulonephritis successfully treated with eculizumab. *Pediatric nephrology*, 30: 1033-1037, 2015.
89. Peffault de Latour, R, Fremeaux-Bacchi, V, Porcher, R, Xhaard, A, Rosain, J, Castaneda, DC, Vieira-Martins, P, Roncelin, S, Rodriguez-Otero, P, Plessier, A, Sicre de Fontbrune, F, Abbes, S, Robin, M, Socie, G: Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. *Blood*, 125: 775-783, 2015.
90. Rigothier, C, Delmas, Y, Roumenina, LT, Contin-Bordes, C, Lepreux, S, Bridoux, F, Goujon, JM, Bachelet, T, Touchard, G, Fremeaux-Bacchi, V, Combe, C: Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgAlambda Antibody. *American journal of kidney diseases : the official journal of the National Kidney Foundation*, 66: 331-336, 2015.
91. Senant, M, Rostane, H, Fernani-Oukil, F, Hosking, F, Bellery, F, Courchinoux, A, Tartour, E, Darnige, L, Dragon-Durey, MA: Increased Performances of the Biological Diagnosis of the Antiphospholipid Syndrome by the Use of a Multiplex Assay. *Journal of immunology research*, 2015: 983094, 2015.
92. Sicard, A, Ducreux, S, Rabeyrin, M, Couzi, L, McGregor, B, Badet, L, Scoazec, JY, Bachelet, T, Lepreux, S, Visentin, J, Merville, P, Fremeaux-Bacchi, V, Morelon, E, Taupin, JL, Dubois, V, Thauinat, O: Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. *Journal of the American Society of Nephrology : JASN*, 26: 457-467, 2015.

93. de Chaisemartin, L, Meatchi, T, Malamut, G, Fernani-Oukil, F, Hosking, F, Rault, D, Bellery, F, Cellier, C, Dragon-Durey, MA: Application of Deamidated Gliadin Antibodies in the Follow-Up of Treated Celiac Disease. *PLoS one*, 10: e0136745, 2015.

94. de Fontbrune, FS, Galambrun, C, Sirvent, A, Huynh, A, Faguer, S, Nguyen, S, Bay, JO, Neven, B, Moussi, J, Simon, L, Xhaard, A, Resche-Riggon, M, O'Meara, A, Fremeaux-Bacchi, V, Veyradier, A, Socie, G, Coppo, P, de Latour, RP: Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC. *Transplantation*, 99: 1953-1959, 2015.

**2014 - Team Cremer/ Teillaud**

95. Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, Lepelley A, Becht E, Katsahian S, Bizouard G, Validire P, Damotte D, Alifano M, Magdeleinat P, Cremer I, Teillaud JL, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC. (2014). Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. *Am J Respir Crit Care Med*. 189:832-44. PMID: 24484236

96. Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, de Chaisemartin L, Ouakrim H, Becht E, Alifano M, Validire P, Remark R, Hammond SA, Cremer I, Damotte D, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC. (2014). Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. *Cancer Res*. 74:705-15. PMID: 24366885

97. Chatterjee S, Crozet L, Damotte D, Iribarren K, Schramm C, Alifano M, Lupo A, Cherfils-Vicini J, Goc J, Katsahian S, Younes M, Dieu-Nosjean MC, Fridman WH, Sautès-Fridman C, Cremer I. (2014). TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer. *Cancer Res*. 74:5008-18. PMID: 25074614

98. Mansuet-Lupo A, Bobbio A, Blons H, Becht E, Ouakrim H, Didelot A, Charpentier MC, Bain S, Marmey B, Bonjour P, Biton J, Cremer I, Dieu-Nosjean MC, Sautès-Fridman C, Régnard JF, Laurent-Puig P, Alifano M, Damotte D. (2014). The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort. *Chest*. 146:633-43. PMID: 24676429

99. ■ Dalmas E, Venteclef N, Caer C, Poitou C, Cremer I, Aron-Wisnewsky J, Lacroix-Desmazes S, Bayry J, Kaveri SV, Clément K, André S, Guerre-Millo M. (2014). T cell-derived IL-22 amplifies IL-18-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes. *Diabetes*. 63:1966-77. PMID: 24520123

100. Messaoudene M, Fregni G, Fourmentraux-Neves E, Chanal J, Maubec E, Mazouz-Dorval S, Couturaud B, Girod A, Sastre-Garau X, Albert S, Guédon C, Deschamps L, Mitilian D, Cremer I, Jacquilot N, Rusakiewicz S, Zitvogel L, Avril MF, Caignard A. (2014). Mature cytotoxic CD56(bright)/CD16(+) natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma. *Cancer Res*. 74:81-92. PMID: 24225017

101. Moog C, Dereuddre-Bosquet N, Teillaud JL, Biedma ME, Holl V, Van Ham G, Heyndrickx L, Van Dorsselaer A, Katinger D, Vcelar B, Zolla-Pazner S, Mangeot I, Kelly C, Shattock RJ, Le Grand R. (2014). Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. *Mucosal Immunol*. 7:46-56. PMID: 23591718

102. Ben Abdelwahed Bagga R, Donnou S, Cosette J, Sautès-Fridman C, Aouni M, Fisson S. (2014). Mouse models of primary central nervous system lymphomas: tools for basing funding and therapeutic strategies. *J Neurooncol*. PMID: 25300908

103. ■ Mlecnik B, Bindea G, Angell HK, Sasso MS, Obenauf AC, Fredriksen T, Lafontaine L, Bilocq AM, Kirilovsky A, Tosolini M, Waldner M, Berger A, Fridman WH, Rafii A, Valge-Archer V, Pagès F, Speicher MR, Galon J. (2014). Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. *Sci Transl Med*. 6:228ra37. PMID: 24648340

104. Younes M, Wu Z, Dupouy S, Lupo AM, Mourra N, Takahashi T, Fléjou JF, Trédaniel J, Régnard JF, Damotte D, Alifano M, Forgez P. (2014). Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib. *Oncotarget*. 5:8252-69. PMID: 25249545

105. Mansuet-Lupo A, Zouiti F, Alifano M, Tallet A, Charpentier MC, Ducruit V, Deveze F, Lemaitre F, Laurent-Puig P, Damotte D, Blons H. (2014). Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis? *J Transl Med*. 12:131. PMID: 24885034

106. Rossille D, Gressier M, Damotte D, Maucort-Boulch D, Pangault C, Semana G, Le Gouill S, Haioun C, Tarte K, Lamy T, Milpied N, Fest T; for the Groupe Ouest-Est des Leucémies et Autres Maladies du Sang; for the Groupe Ouest-Est des Leucémies et Autres Maladies du Sang. (2014). High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. *Leukemia*. 28:2367-75. PMID: 24732592

107. Strano S, Damotte D, Alifano M. (2014). Reply: To PMID 23415237. *Ann Thorac Surg*. 97:381-2. PMID: 24384209

108. Legras A, Mansuet-Lupo A, Rousset-Jablonski C, Bobbio A, Magdeleinat P, Roche N, Regnard JF, Gompel A, Damotte D, Alifano M. (2014). Pneumothorax in women of child-bearing age: an update classification based on clinical and pathologic findings. *Chest*. 145:354-60. PMID: 24091546



109. Sivaraman A, Sanchez-Salas R, Barret E, Macek P, Validire P, Galiano M, Rozet F, Cathelineau X. (2014). Prostate histoscanning true targeting guided prostate biopsy: initial clinical experience. *World J Urol*. PMID: 25501797
110. Stern JB, Wyplosz B, Validire P, Angoulvant A, Fregeville A, Caliandro R, Gossot D. (2014). Bulky mediastinal aspergillosis mimicking cancer in an immunocompetent patient. *Ann Thorac Surg*. 98:1472-5. PMID: 25282220
111. Sargent DJ, Shi Q, Gill S, Louvet C, Everson RB, Kellner U, Clancy TE, Pipas JM, Resnick MB, Meyers MO, Wu TT, Huntsman D, Validire P, Farooq U, Pavey ES, Beaudry G, Haince JF, Fradet Y. (2014). Molecular testing for lymph node metastases as a determinant of colon cancer recurrence: results from a retrospective multicenter study. *Clin Cancer Res*. 20:4361-9. PMID: 24919572
112. Zaanan A, Dalban C, Emile JF, Blons H, Fléjou JF, Goumard C, Istanbulu M, Calmel C, Alhazmi K, Validire P, Louvet C, de Gramont A, Laurent-Puig P, Taïeb J, Praz F. (2014). ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy. *J Cancer*. 5:425-32. PMID: 24847383
113. Hasmats J, Gréen H, Orear C, Validire P, Huss M, Käller M, Lundeberg J. (2014). Assessment of whole genome amplification for sequence capture and massively parallel sequencing. *PLoS One*. 9:e84785. PMID: 24409309
114. Macek P, Barret E, Sanchez-Salas R, Galiano M, Rozet F, Ahallal Y, Gaya JM, Durant M, Mascle L, Giedelman C, Lunelli L, Validire P, Nesvadba M, Cathelineau X. (2014). Prostate histoscanning in clinically localized biopsy proven prostate cancer: an accuracy study. *J Endourol*. 28:371-6. PMID: 24032370

#### 2014 - Fremeaux-Bacchi

115. Marinozzi, MC, Vergoz, L, Rybkine, T, Ngo, S, Bettoni, S, Pashov, A, Cayla, M, Tabarin, F, Jablonski, M, Hue, C, Smith, RJ, Noris, M, Halbwachs-Mecarelli, L, Donadelli, R, Fremeaux-Bacchi, V, Roumenina, LT: Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign? *Journal of the American Society of Nephrology : JASN*, 25: 2053-2065, 2014.
116. ■ Rayes, J, Roumenina, LT, Dimitrov, JD, Repesse, Y, Ing, M, Christophe, O, Jokiranta, TS, Halbwachs-Mecarelli, L, Borel-Derlon, A, Kaveri, SV, Fremeaux-Bacchi, V, Lacroix-Desmazes, S: The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. *Blood*, 123: 121-125, 2014.
117. Canaud, G, Bienaime, F, Tabarin, F, Bataillon, G, Seilhean, D, Noel, LH, Dragon-Durey, MA, Snanoudj, R, Friedlander, G, Halbwachs-Mecarelli, L, Legendre, C, Terzi, F: Inhibition of the mTORC pathway in the antiphospholipid syndrome. *The New England journal of medicine*, 371: 303-312, 2014.
118. ■ Figueres, ML, Fremeaux-Bacchi, V, Rabant, M, Galmiche, L, Marinozzi, MC, Grunfeld, JP, Noel, LH, Servais, A: Heterogeneous histologic and clinical evolution in 3 cases of dense deposit disease with long-term follow-up. *Human pathology*, 45: 2326-2333, 2014.
119. Cornec-Le Gall, E, Delmas, Y, De Parscau, L, Doucet, L, Ogier, H, Benoist, JF, Fremeaux-Bacchi, V, Le Meur, Y: Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. *American journal of kidney diseases : the official journal of the National Kidney Foundation*, 63: 119-123, 2014.
120. Fakhouri, F, Delmas, Y, Provot, F, Barbet, C, Karras, A, Makdassi, R, Courivaud, C, Rifard, K, Servais, A, Allard, C, Besson, V, Cousin, M, Chatelet, V, Goujon, JM, Coindre, JP, Laurent, G, Loirat, C, Fremeaux-Bacchi, V: Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. *American journal of kidney diseases : the official journal of the National Kidney Foundation*, 63: 40-48, 2014.
121. Gaschignard, J, Levy, C, Chrabieh, M, Boisson, B, Bost-Bru, C, Dager, S, Dubos, F, Durand, P, Gaudelus, J, Gendrel, D, Gras Le Guen, C, Grimprel, E, Guyon, G, Jeudy, C, Jeziorski, E, Leclerc, F, Leger, PL, Lesage, F, Lorrot, M, Pellier, I, Pinquier, D, de Pontual, L, Sachs, P, Thomas, C, Tissieres, P, Valla, FV, Desprez, P, Fremeaux-Bacchi, V, Varon, E, Bossuyt, X, Cohen, R, Abel, L, Casanova, JL, Puel, A, Picard, C: Invasive pneumococcal disease in children can reveal a primary immunodeficiency. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, 59: 244-251, 2014.
122. Nicolas, C, Vuiblet, V, Baudouin, V, Macher, MA, Vrillon, I, Biebuyck-Gouge, N, Dehennault, M, Gie, S, Morin, D, Nivet, H, Nobili, F, Ulinski, T, Ranchin, B, Marinozzi, MC, Ngo, S, Fremeaux-Bacchi, V, Pietrement, C: C3 nephritic factor associated with C3 glomerulopathy in children. *Pediatric nephrology*, 29: 85-94, 2014.
123. Riedl, M, Fakhouri, F, Le Quintrec, M, Noone, DG, Jungraithmayr, TC, Fremeaux-Bacchi, V, Licht, C: Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. *Seminars in thrombosis and hemostasis*, 40: 444-464, 2014.

124. Rondelli, T, Risitano, AM, Peffault de Latour, R, Sica, M, Peruzzi, B, Ricci, P, Barcellini, W, Iori, AP, Boschetti, C, Valle, V, Fremeaux-Bacchi, V, De Angioletti, M, Socie, G, Luzzatto, L, Notaro, R: Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria. *Haematologica*, 99: 262-266, 2014.
125. Sana, G, Dragon-Durey, MA, Charbit, M, Bouchireb, K, Rousset-Rouviere, C, Berard, E, Salomon, R, Fremeaux-Bacchi, V, Niaudet, P, Boyer, O: Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. *Pediatric nephrology*, 29: 75-83, 2014.
126. Sinha, A, Gulati, A, Saini, S, Blanc, C, Gupta, A, Gurjar, BS, Saini, H, Kotresh, ST, Ali, U, Bhatia, D, Ohri, A, Kumar, M, Agarwal, I, Gulati, S, Anand, K, Vijayakumar, M, Sinha, R, Sethi, S, Salmona, M, George, A, Bal, V, Singh, G, Dinda, AK, Hari, P, Rath, S, Dragon-Durey, MA, Bagga, A, Indian, HUSR: Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. *Kidney international*, 85: 1151-1160, 2014
127. Visentin, J, Vigata, M, Daburon, S, Contin-Bordes, C, Fremeaux-Bacchi, V, Dromer, C, Billes, MA, Neau-Cransac, M, Guidicelli, G, Taupin, JL: Deciphering complement interference in anti-human leukocyte antigen antibody detection with flow beads assays. *Transplantation*, 98: 625-631, 2014.
128. Watson, R, Lindner, S, Bordereau, P, Hunze, EM, Tak, F, Ngo, S, Zipfel, PF, Skerka, C, Dragon-Durey, MA, Marchbank, KJ: Standardisation of the factor H autoantibody assay. *Immunobiology*, 219: 9-16, 2014.
129. Berthe-Aucejo, A, Sacquepee, M, Fila, M, Peuchmaur, M, Perrier-Cornet, E, Fremeaux-Bacchi, V, Deschenes, G: Blockade of alternative complement pathway in dense deposit disease. *Case reports in nephrology*, 2014: 201568, 2014.
130. Westland, R, Bodria, M, Carrea, A, Lata, S, Scolari, F, Fremeaux-Bacchi, V, D'Agati, VD, Lifton, RP, Gharavi, AG, Ghiggeri, GM, Sanna-Cherchi, S: Phenotypic expansion of DGKE-associated diseases. *Journal of the American Society of Nephrology : JASN*, 25: 1408-1414, 2014.

#### 2013 - Team Cremer/ Teillaud

131. ■ Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean MC, Riquet M, Crozet L, Ouakrim H, Goc J, Cazes A, Fléjou JF, Gibault L, Verkarre V, Régnard JF, Pagès ON, Oudard S, Mlecnik B, Sautès-Fridman C, Fridman WH, Damotte D. (2013). Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. *Clin Cancer Res*. 19:4079-91. PMID: 23785047
132. Gillard-Bocquet M, Caer C, Cagnard N, Crozet L, Perez M, Fridman WH, Sautès-Fridman C, Cremer I. (2013). Lung tumor microenvironment induces specific gene expression signature in intratumoral NK cells. *Front Immunol*. 4:19. PMID: 23382731
133. Rozan C, Cornillon A, Pétiard C, Chartier M, Behar G, Boix C, Kerfelec B, Robert B, Pèlegri A, Chames P, Teillaud JL, Baty D. (2013). Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells. *Mol Cancer Ther*. 12:1481-91. PMID: 23757164
134. Fregni G, Messaoudene M, Fourmentraux-Neves E, Mazouz-Dorval S, Chanal J, Maubec E, Marinho E, Scheer-Senyarich I, Cremer I, Avril MF, Caignard A. (2013). Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages. *PLoS One*. 8:e76928. PMID: 24204708
135. ■ Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, Vimond N, Concha A, Garrido F, Isabert N, Chaigneau L, Le Brun-Ly V, Dubreuil P, Cremer I, Caignard A, Poirier-Colame V, Chaba K, Flament C, Halama N, Jäger D, Eggermont A, Bonvalot S, Commo F, Terrier P, Opolon P, Emile JF, Coindre JM, Kroemer G, Chaput N, Le Cesne A, Blay JY, Zitvogel L. (2013). Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. *Cancer Res*. 73:3499-510. PMID: 23592754
136. Pizzurro GA, Madorsky Rowdo FP, Pujol-Lereis LM, Quesada-Allué LA, Copati AM, Roberti MP, Teillaud JL, Levy EM, Barrio MM, Mordoh J. (2013). High lipid content of irradiated human melanoma cells does not affect cytokine-matured dendritic cell function. *Cancer Immunol Immunother*. 62:3-15. PMID: 22722447
137. Ben Abdelwahed R, Donnou S, Ouakrim H, Crozet L, Cosette J, Jacquet A, Tourais I, Fournès B, Gillard Bocquet M, Miloudi A, Touitou V, Daussy C, Naud MC, Fridman WH, Sautès-Fridman C, Urbain R, Fisson S. (2013). Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas. *Invest Ophthalmol Vis Sci*. 54:3657-65. PMID: 23611989
138. Ben Abdelwahed R, Cosette J, Donnou S, Crozet L, Ouakrim H, Fridman WH, Sautès-Fridman C, Mahjoub A, Fisson S. (2013). Lymphoma B-cell responsiveness to CpG-DNA depends on the tumor microenvironment. *J Exp Clin Cancer Res*. 32:18. PMID: 23561041
139. Fisson S, Ouakrim H, Touitou V, Baudet S, Ben Abdelwahed R, Donnou S, Miloudi A, Galand C, Bodaghi B, Lehoang P, Brissard M, Le Garff-Tavernier M, Fridman WH, Sautès-Fridman C, Cassoux N, Merle-Béral H. (2013). Cytokine profile in human eyes: contribution of a new cytokine combination for differential diagnosis between intraocular lymphoma or uveitis. *PLoS One*. 8:e52385. PMID: 23405064

140. Lazar V, Suo C, Orear C, van den Oord J, Balogh Z, Guegan J, Job B, Meurice G, Ripoché H, Calza S, Hasmats J, Lundeberg J, Lacroix L, Vielh P, Dufour F, Lehtiö J, Napieralski R, Eggermont A, Schmitt M, Cadranel J, Besse B, Girard P, Blackhall F, **Validire P**, Soria JC, Dessen P, Hansson J, Pawitan Y. (2013). Integrated molecular portrait of non-small cell lung cancers. *BMC Med Genomics*. 6:53. PMID: 24299561
141. Watson S, **Validire P**, Cervera P, Zorkani N, Scriva A, Lemay F, Tournigand C, Perniceni T, Garcia ML, Bennamoun M, Paye F, Louvet C. (2013). Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study. *Ann Oncol*. 24:3035-9. PMID: 24114855
142. Pernemalm M, De Petris L, Branca RM, Forshed J, Kanter L, Soria JC, Girard P, **Validire P**, Pawitan Y, van den Oord J, Lazar V, Pählman S, Lewensohn R, Lehtiö J. (2013). Quantitative proteomics profiling of primary lung adenocarcinoma tumors reveals functional perturbations in tumor metabolism. *J Proteome Res*. 12:3934-43. PMID: 23902561
143. Pierangelo A, Nazac A, Benali A, **Validire P**, Cohen H, Novikova T, Ibrahim BH, Manhas S, Fallet C, Antonelli MR, Martino AD. (2013). Polarimetric imaging of uterine cervix: a case study. *Opt Express*. 21:14120-30. PMID: 23787602
144. Vanhecke E, Valent A, Tang X, Vielh P, Friboulet L, Tang T, Goubar A, Li Y, Robin A, Behrens C, Commo F, **Validire P**, André F, Wistuba II, Soria JC, Olausson KA. (2013). 19q13-ERCC1 gene copy number increase in non-small-cell lung cancer. *Clin Lung Cancer*. 14:549-57. PMID: 23773262
145. Delyon J, Bézier M, Rybojad M, Brière J, **Validire P**, Bagot M, Janin A, Battistella M. (2013) Specific lymph node involvement in scleromyxedema: a new diagnostic entity for hypermetabolic lymphadenopathy. *Virchows Arch*. 462:679-83. PMID: 23681113
146. Pierangelo A, Manhas S, Benali A, Fallet C, Totobenazara JL, Antonelli MR, Novikova T, Gayet B, De Martino A, **Validire P**. (2013). Multispectral Mueller polarimetric imaging detecting residual cancer and cancer regression after neoadjuvant treatment for colorectal carcinomas. *J Biomed Opt*. 18:046014. PMID: 23612875
147. Mazières J, Rouquette I, Lepage B, Milia J, Brouchet L, Guibert N, Beau-Faller M, **Validire P**, Hofman P, Fouret P. (2013). Specificities of lung adenocarcinoma in women who have never smoked. *J Thorac Oncol*. 8:923-9. PMID: 23608817
148. Weiswald LB, Richon S, Massonnet G, Guinebretière JM, Vacher S, Laurendeau I, Cottu P, Marangoni E, Nemati F, **Validire P**, Bellet D, Bièche I, Dangles-Marie V. (2013). A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation. *Br J Cancer*. 108:1720-31. PMID: 23538387
149. Andujar P, Paireon JC, Renier A, Descatha A, Hysi I, Abd-alsamad I, Billon-Galland MA, Blons H, Clin B, Danel C, Debrosse D, Galateau-Sallé F, Housset B, Laurent-Puig P, Le Pimpec-Barthes F, Letourneux M, Monnet I, Régnard JF, **Validire P**, Zucman-Rossi J, Jaurand MC, Jean D. (2013). Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. *Mutagenesis*. 28:323-31. PMID: 23435014
150. Galluzzi L, Goubar A, Olausson KA, Vitale I, Senovilla L, Michels J, Robin A, Dorvault N, Besse B, **Validire P**, Fouret P, Behrens C, Wistuba II, Soria JC, Kroemer G. (2013). Prognostic value of LIPC in non-small cell lung carcinoma. *Cell Cycle*. 12:647-54. PMID: 23343765
151. Dagouassat M, Gagliolo JM, Chrusciel S, Bourin MC, Duprez C, Caramelle P, Boyer L, Hue S, Stern JB, **Validire P**, Longrois D, Norel X, Dubois-Randé JL, Le Gouvello S, Adnot S, Boczkowski J. (2013). The cyclooxygenase-2-prostaglandin E2 pathway maintains senescence of chronic obstructive pulmonary disease fibroblasts. *Am J Respir Crit Care Med*. 187:703-14. PMID: 23328527
152. Barret E, Ahallal Y, Sanchez-Salas R, Galiano M, Cosset JM, **Validire P**, Macek P, Durand M, Prapotnich D, Rozet F, Cathelineau X. (2013). Morbidity of focal therapy in the treatment of localized prostate cancer. *Eur Urol*. 63:618-22. PMID: 23265382
153. Galeone A, **Validire P**, Debrosse D, Folliguet T, Laborde F. (2013). Leiomyosarcoma of the right inferior pulmonary vein: 2 years survival with multimodality therapy. *Gen Thorac Cardiovasc Surg*. 61:534-7. PMID: 23224659
154. Rouprêt M, Seisen T, Compérat E, Larré S, Mazerolles C, Gobet F, Fetissof F, Fromont G, Safsaf A, d'Arcier BF, Celhay O, **Validire P**, Rozet F, Irani J, Soulié M, Pfister C; Comité de Cancérologie de l'Association Française d'Urologie. (2013). Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review. *J Urol*. 189:2069-76. PMID: 23201497
155. Gyan E, **Damotte D**, Courby S, Sénécal D, Quittet P, Schmidt-Tanguy A, Banos A, Le Gouill S, Lamy T, Fontan J, Maisonneuve H, Alexis M, Dreyfus F, Tournilhac O, Laribi K, Solal-Céligny P, Arakelyan N, Cartron G, Gressin R; GOELAMS Group. (2013). High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study. *Br J Haematol*. 162:240-9. PMID: 23692641
156. Strano S, Lupo A, Lococo F, Schussler O, Loi M, Younes M, Bobbio A, **Damotte D**, Regnard JF, Alifano M. (2013). Prognostic significance of vascular and lymphatic emboli in resected pulmonary adenocarcinoma. *Ann Thorac Surg*. 95:1204-10. PMID: 23415237
157. Le Treut J, Sault MC, Lena H, Souquet PJ, Vergnenegre A, Le Caer H, Berard H, Boffa S, Monnet I, **Damotte D**, Chouaid C. (2013). Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. *Ann Oncol*. 24:1548-52. PMID: 23406729

158. Baud M, Strano S, Dechartres A, Jouni R, Triponez F, Chouaid C, Forgez P, Damotte D, Roche N, Régnard JF, Alifano M. (2013). Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis. *J Thorac Cardiovasc Surg*. 145:1305-11. PMID: 23072703
159. Fournel L, Falcoz PE, Alifano M, Charpentier MC, Boudaya MS, Magdeleinat P, Damotte D, Régnard JF. (2013). Surgical management of pulmonary large cell neuroendocrine carcinomas: a 10-year experience. *Eur J Cardiothorac Surg*. 43:111-4. PMID: 22529187
160. ■ Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenaus AC, Angell H, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C, Pagès F, Speicher MR, Trajanoski Z, Galon J. (2013). Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. *Immunity*. 39:782-95. PMID: 24138885
161. Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, Levionnois E, Nizard M, Si-Mohamed A, Besnier N, Gey A, Rotem-Yehudar R, Pere H, Tran T, Guerin CL, Chauvat A, Dransart E, Alanio C, Albert S, Barry B, Sandoval F, Quintin-Colonna F, Bruneval P, Fridman WH, Lemoine FM, Oudard S, Johannes L, Olive D, Brasnu D, Tartour E. (2013). PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. *Cancer Res*. 73:128-38. PMID: 23135914
162. Gaspar K, Kukova G, Bunemann E, Bühren BA, Sonkoly E, Szollosi AG, Müller A, Savinko T, Lauerma AI, Alenius H, Kemeny L, Dieu-Nosjean MC, Stander S, Fischer JW, Ruzicka T, Zlotnik A, Szegei A, Homey B. (2013). The chemokine receptor CCR3 participates in tissue remodeling during atopic skin inflammation. *J Dermatol Sci*. 71:12-21. PMID: 23702389
163. 📧 Gérard S, Sibérlil S, Martin E, Lenoir C, Aguilar C, Picard C, Lantz O, Fischer A, Latour S. (2013). Human iNKT and MAIT cells exhibit a PLZF-dependent proapoptotic propensity that is counterbalanced by XIAP. *Blood*. 121:614-23. PMID: 23223428

### 2013 - Fremeaux-Bacchi

164. Lemaire, M, Fremeaux-Bacchi, V, Schaefer, F, Choi, M, Tang, WH, Le Quintrec, M, Fakhouri, F, Taque, S, Nobili, F, Martinez, F, Ji, W, Overton, JD, Mane, SM, Nurnberg, G, Altmüller, J, Thiele, H, Morin, D, Deschenes, G, Baudouin, V, Llanas, B, Collard, L, Majid, MA, Simkova, E, Nurnberg, P, Rioux-Leclerc, N, Moeckel, GW, Gubler, MC, Hwa, J, Loirat, C, Lifton, RP: Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. *Nature genetics*, 45: 531-536, 2013.
165. ■ Frimat, M, Tabarin, F, Dimitrov, JD, Poitou, C, Halbwachs-Mecarelli, L, Fremeaux-Bacchi, V, Roumenina, LT: Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. *Blood*, 122: 282-292, 2013.
166. Fremeaux-Bacchi, V, Fakhouri, F, Garnier, A, Bienaime, F, Dragon-Durey, MA, Ngo, S, Moulin, B, Servais, A, Provot, F, Rostaing, L, Burtsey, S, Niaudet, P, Deschenes, G, Lebranchu, Y, Zuber, J, Loirat, C: Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. *Clinical journal of the American Society of Nephrology : CJASN*, 8: 554-562, 2013.
167. Loupy, A, Lefaucheur, C, Vernerey, D, Prugger, C, Duong van Huyen, JP, Mooney, N, Suberbielle, C, Fremeaux-Bacchi, V, Mejean, A, Desgrandchamps, F, Anglicheau, D, Nochy, D, Charron, D, Empana, JP, Delahousse, M, Legendre, C, Glotz, D, Hill, GS, Zeevi, A, Jouven, X: Complement-binding anti-HLA antibodies and kidney-allograft survival. *The New England journal of medicine*, 369: 1215-1226, 2013.
168. Le Quintrec, M, Zuber, J, Moulin, B, Kamar, N, Jablonski, M, Lionet, A, Chatelet, V, Mousson, C, Mourad, G, Bridoux, F, Cassuto, E, Loirat, C, Rondeau, E, Delahousse, M, Fremeaux-Bacchi, V: Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*, 13: 663-675, 2013.
169. Bekassy, ZD, Kristoffersson, AC, Cronqvist, M, Roumenina, LT, Rybkine, T, Vergoz, L, Hue, C, Fremeaux-Bacchi, V, Karpman, D: Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*, 28: 2899-2907, 2013.
170. Bresin, E, Rurali, E, Caprioli, J, Sanchez-Corral, P, Fremeaux-Bacchi, V, Rodriguez de Cordoba, S, Pinto, S, Goodship, TH, Alberti, M, Ribes, D, Valoti, E, Remuzzi, G, Noris, M, European Working Party on Complement Genetics in Renal, D: Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. *Journal of the American Society of Nephrology : JASN*, 24: 475-486, 2013.
171. Hebecker, M, Alba-Dominguez, M, Roumenina, LT, Reuter, S, Hyvarinen, S, Dragon-Durey, MA, Jokiranta, TS, Sanchez-Corral, P, Jozsi, M: An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H. *Journal of immunology*, 191: 912-921, 2013.

172. Haerynck, F, Stordeur, P, Vandewalle, J, Van Coster, R, Bordon, V, De Baets, F, Schelstraete, P, Javaux, C, Bouvry, MR, Fremaux-Bacchi, V, Dehoorne, J: Complete factor I deficiency due to dysfunctional factor I with recurrent aseptic meningitis-encephalitis. *Journal of clinical immunology*, 33: 1293-1301, 2013.
173. Mohlin, FC, Mercier, E, Fremaux-Bacchi, V, Liszewski, MK, Atkinson, JP, Gris, JC, Blom, AM: Analysis of genes coding for CD46, CD55, and C4b-binding protein in patients with idiopathic, recurrent, spontaneous pregnancy loss. *European journal of immunology*, 43: 1617-1629, 2013.
174. Peffault de Latour, R, Xhaard, A, Fremaux-Bacchi, V, Coppo, P, Fischer, AM, Helley, D, Socie, G: Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy. *British journal of haematology*, 161: 279-280, 2013.

## 2012 - Team Cremer/ Teillaud

175. Sib riel S, M enez R, Jorieux S, de Romeuf C, Bourel D, Fridman WH, Ducancel F, Stura EA, Teillaud JL. (2012). Effect of zinc on human IgG1 and its FcγR interactions. *Immunol Lett.* 143:60-9. PMID: 22553781
176. Peifer M, Fern andez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, M ller C, Di Cerbo V, Schildhaus HU, Altm ller J, Baessmann I, Becker C, de Wilde B, Vandesompele J, B hm D, Ans n S, Gabler F, Wilkening I, Heynck S, Heuckmann JM, Lu X, Carter SL, Cibulskis K, Banerji S, Getz G, Park KS, Rauh D, Gr tter C, Fischer M, Pasqualucci L, Wright G, Wainer Z, Russell P, Petersen I, Chen Y, Stoelben E, Ludwig C, Schnabel P, Hoffmann H, Muley T, Brockmann M, Engel-Riedel W, Muscarella LA, Fazio VM, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman DA, Snijders PJ, Cappuzzo F, Ligorio C, Damiani S, Field J, Solberg S, Brustugun OT, Lund-Iversen M, S nger J, Clement JH, Soltermann A, Moch H, Weder W, Solomon B, Soria JC, Validire P, Besse B, Brambilla E, Brambilla C, Lantuejoul S, Lorimier P, Schneider PM, Hallek M, Pao W, Meyerson M, Sage J, Shendure J, Schneider R, B ttner R, Wolf J, N rnberg P, Perner S, Heukamp LC, Brindle PK, Haas S, Thomas RK. (2012). Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. *Nat Genet.* 44:1104-10. PMID: 22941188
177. Fouret R, Laffaire J, Hofman P, Beau-Faller M, Mazieres J, Validire P, Girard P, Camilleri-Br et S, Vaylet F, Leroy-Ladurie F, Soria JC, Fouret P. (2012). A comparative and integrative approach identifies ATPase family, AAA domain containing 2 as a likely driver of cell proliferation in lung adenocarcinoma. *Clin Cancer Res.* 18:5606-16. PMID: 22914773
178. ■ Galluzzi L, Vitale I, Senovilla L, Olaussen KA, Pinna G, Eisenberg T, Goubar A, Martins I, Michels J, Kratassiouk G, Carmona-Gutierrez D, Scoazec M, Vacchelli E, Schlemmer F, Kepp O, Shen S, Tailler M, Niso-Santano M, Morselli E, Criollo A, Adjemian S, Jema  M, Chaba K, Pailleret C, Michaud M, Pietrocola F, Tajeddine N, de La Motte Rouge T, Araujo N, Morozova N, Robert T, Ripoche H, Commo F, Besse B, Validire P, Fouret P, Robin A, Dorvault N, Girard P, Gouy S, Pautier J, J gemann N, Nickel AC, Marsili S, Paccard C, Servant N, Hup  P, Behrens C, Behnam-Motlagh P, Kohno K, Cremer I, Damotte D, Alifano M, Midttun O, Ueland PM, Lazar V, Dessen P, Zischka H, Chatelut E, Castedo M, Madeo F, Barillot E, Thomale J, Wistuba II, Saut s-Fridman C, Zitvogel L, Soria JC, Harel-Bellan A, Kroemer G. (2012). Prognostic impact of vitamin B6 metabolism in lung cancer. *Cell Rep.* 2:257-69. PMID: 22854025
179. Hasmats J, Green H, Solnestam BW, Zajac P, Huss M, Orear C, Validire P, Bjursell M, Lundeberg J. (2012). Validation of whole genome amplification for analysis of the p53 tumor suppressor gene in limited amounts of tumor samples. *Biochem Biophys Res Commun.* 425:379-83. PMID: 22842464
180. Pierangelo A, Manhas S, Benali A, Fallet C, Antonelli MR, Novikova T, Gayet B, Validire P, De Martino A. (2012). Ex vivo photometric and polarimetric multilayer characterization of human healthy colon by multispectral Mueller imaging. *J Biomed Opt.* 17:066009. PMID: 22734765
181. Zanni M, Moulin-Romsee G, Servois V, Validire P, B namor M, Plancher C, Rouic LL, Dendale R, Vincent-Salomon A, Asselain B, Sahli R, Decaudin D. (2012). Value of 18FDG PET scan in staging of ocular adnexal lymphomas: a large single-center experience *Hematology.* 17:76-84. PMID: 22664045
182. Salmon H, Franciszkiwicz K, Damotte D, Dieu-Nosjean MC, Validire P, Trautmann A, Mami-Chouaib F, Donnadieu E. (2012). Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. *J Clin Invest.* 122:899-910. PMID: 22293174
183. Ramos R, Girard P, Masuet C, Validire P, Gossot D. (2012). Mediastinal lymph node dissection in early-stage non-small cell lung cancer: totally thorascopic vs thoracotomy. *Eur J Cardiothorac Surg.* 41:1342-8; discussion 1348. PMID: 22228841
184. Hofman P, Ilie M, Hofman V, Roux S, Valent A, Bernheim A, Alifano M, Leroy-Ladurie F, Vaylet F, Rouquette I, Validire P, Beau-Faller M, Lacroix L, Soria JC, Fouret P. (2012). Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. *Ann Oncol.* 23:1738-43. PMID: 22100693
185. Guinet C, Rousset P, Bobbio A, Alifano M, Damotte D, R gnard JF, Buy JN. (2012). Comparison of coronal and axial computed tomography measurements of mediastinal nodes before primary surgery for non-small cell lung cancer. *Eur J Radiol.* 81:2440-3. PMID: 21703790
186. ■ Pere H, Tanchot C, Bayry J, Terme M, Taieb J, Badoual C, Adotevi O, Merillon N, Marcheteau E, Quillien VR, Banissi C, Carpentier A, Sandoval F, Nizard M, Quintin-Colonna F, Kroemer G, Fridman WH,

Zitvogel L, Oudard SP, Tartour E. (2012). Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. *Oncoimmunology*. 1:326-333. PMID: 22737608

187. Chauvat A, Benhamouda N, Loison E, Gougeon ML, Gey A, Levionnois E, Ravel P, Abitbol V, Roncelin S, Marcheteau E, Quintin-Colonna F, Fridman WH, Launay O, Tartour E. (2012). Pitfalls in anti-influenza T cell detection by Elispot using thimerosal containing pandemic H1N1 vaccine as antigen. *J Immunol Methods*. 378:81-7. PMID: 22366633

188. Berinstein NL, Wolf GT, Naylor PH, Baltzer L, Egan JE, Brandwein HJ, Whiteside TL, Goldstein LC, El-Naggar A, Badoual C, Fridman WH, White JM, Hadden JW. (2012). Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. *Cancer Immunol Immunother*. 61:771-82. PMID: 22057678

189. Reynaud CA, Moutel S, Dieu-Nosjean MC, Laskov R, Teillaud JL. (2012). 1(st) French-Israeli International Conference on B Cells and therapeutic antibodies: October 23-25, 2011 Jerusalem, Israel. *MABS*. 4:426-33. PMID: 22664457

## 2012 - Fremeaux-Bacchi

190. Roumenina, LT, Frimat, M, Miller, EC, Provot, F, Dragon-Durey, MA, Bordereau, P, Bigot, S, Hue, C, Satchell, SC, Mathieson, PW, Mousson, C, Noel, C, Sautes-Fridman, C, Halbwachs-Mecarelli, L, Atkinson, JP, Lionet, A, Fremeaux-Bacchi, V: A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. *Blood*, 119: 4182-4191, 2012.

191. Blanc, C, Roumenina, LT, Ashraf, Y, Hyvarinen, S, Sethi, SK, Ranchin, B, Niaudet, P, Loirat, C, Gulati, A, Bagga, A, Fridman, WH, Sautes-Fridman, C, Jokiranta, TS, Fremeaux-Bacchi, V, Dragon-Durey, MA: Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. *Journal of immunology*, 189: 3528-3537, 2012.

192. Servais, A, Noel, LH, Roumenina, LT, Le Quintrec, M, Ngo, S, Dragon-Durey, MA, Macher, MA, Zuber, J, Karras, A, Provot, F, Moulin, B, Grunfeld, JP, Niaudet, P, Lesavre, P, Fremeaux-Bacchi, V: Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. *Kidney international*, 82: 454-464, 2012.

193. Le Friec, G, Sheppard, D, Whiteman, P, Karsten, CM, Shamoun, SA, Laing, A, Bugeon, L, Dallman, MJ, Melchionna, T, Chillakuri, C, Smith, RA, Drouet, C, Couzi, L, Fremeaux-Bacchi, V, Kohl, J, Waddington, SN, McDonnell, JM, Baker, A, Handford, PA, Lea, SM, Kemper, C: The CD46-Jagged1 interaction is critical for human TH1 immunity. *Nature immunology*, 13: 1213-1221, 2012.

194. El Karoui, K, Hill, GS, Karras, A, Jacquot, C, Moulouquet, L, Kourilsky, O, Fremeaux-Bacchi, V, Delahousse, M, Duong Van Huyen, JP, Loupy, A, Bruneval, P, Nochy, D: A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. *Journal of the American Society of Nephrology : JASN*, 23: 137-148, 2012.

195. Ermini, L, Goodship, TH, Strain, L, Weale, ME, Sacks, SH, Cordell, HJ, Fremeaux-Bacchi, V, Sheerin, NS: Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. *Molecular immunology*, 49: 640-648, 2012.

196. Krid, S, Roumenina, LT, Beury, D, Charbit, M, Boyer, O, Fremeaux-Bacchi, V, Niaudet, P: Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*, 12: 1938-1944, 2012.

197. Sartz, L, Olin, AI, Kristoffersson, AC, Stahl, AL, Johansson, ME, Westman, K, Fremeaux-Bacchi, V, Nilsson-Ekdahl, K, Karpman, D: A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome. *Journal of immunology*, 188: 2030-2037, 2012.

198. Vanhecke, D, Roumenina, LT, Wan, H, Osthoff, M, Schaller, M, Trendelenburg, M: Identification of a major linear C1q epitope allows detection of systemic lupus erythematosus anti-C1q antibodies by a specific peptide-based enzyme-linked immunosorbent assay. *Arthritis and rheumatism*, 64: 3706-3714, 2012.

199. Vernon, KA, Goicoechea de Jorge, E, Hall, AE, Fremeaux-Bacchi, V, Aitman, TJ, Cook, HT, Hangartner, R, Koziell, A, Pickering, MC: Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency. *American journal of kidney diseases : the official journal of the National Kidney Foundation*, 60: 121-125, 2012.

200. Zuber, J, Le Quintrec, M, Krid, S, Bertoye, C, Gueutin, V, Lahoche, A, Heyne, N, Ardissino, G, Chatelet, V, Noel, LH, Hourmant, M, Niaudet, P, Fremeaux-Bacchi, V, Rondeau, E, Legendre, C, Loirat, C, French Study Group for Atypical, HUS: Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*, 12: 3337-3354, 2012.

## Articles de synthèse / revues bibliographiques

## 2017 - Team Cremer/ Teillaud

1. ■ Fridman WH., Zitvogel L., Sautès-Fridman C., Kroemer G., The immune contexture in cancer prognosis and treatment. *Nat. Rev. Clin. Onc.* 2017, in press
2. Duruisseaux M, Rouquette I, Adam J, Cortot A, Cazes A, Gibault L, Damotte D, Lantuejoul S. (2017) [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers]. *Ann Pathol.* Feb;37(1):61-78. PMID:28162296
3. Burroni B, Broudin C, Damotte D, Laurent C. (2017) [Immune-checkpoint and hemopathies]. *Ann Pathol.* Feb;37(1):101-110. PMID:28161001

## 2017 - Fremeaux-Bacchi

4. Fakhouri, F., Zuber, J., Fremeaux-Bacchi, V., and Loirat, C. (2017) Haemolytic uraemic syndrome, *Lancet.*, in press
5. Goodship, T. H., Cook, H. T., Fakhouri, F., Fervenza, F. C., Fremeaux-Bacchi, V., Kavanagh, D., Nester, C. M., Noris, M., Pickering, M. C., Rodriguez de Cordoba, S., Roumenina, L. T., Sethi, S., Smith, R. J., and Conference, P. (2017) Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference, *Kidney international* 91, 539-551.
6. Joste, V., Dragon-Durey, M. A., and Darnige, L. (2017) [Laboratory diagnosis of antiphospholipid syndrome: From criteria to practice], *La Revue de medecine interne.*
7. ■ Daugan, M., Noe, R., Sautès-Fridman, C., Fridman, WH., Roumenina, LT., [Le système du complément : une épée à double tranchant dans la progression tumorale], *Médecine/Sciences*, 2017, in press

## 2016 - Team Cremer/ Teillaud

8. Becht E, Giraldo NA, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH. (2016) Cancer immune contexture and immunotherapy. *Curr Opin Immunol.* 39:7-13. Review. PMID: 26708937
9. Dieu-Nosjean MC, Giraldo NA, Kaplon H, Germain C, Fridman WH, Sautès-Fridman C. (2016) Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. *Immunol Rev.* 271:260-75. Review. PMID: 27088920
10. Becht E, Giraldo NA, Germain C, de Reyniès A, Laurent-Puig P, Zucman-Rossi J, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH. (2016) Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. *Adv Immunol.* 130:95-190. PMID: 26923001
11. ■ Fucikova J, Becht E, Iribarren K, Goc J, Remark R, Damotte D, Alifano M, Devi P, Biton J, Germain C, Lupo A, Fridman WH, Dieu-Nosjean MC, Kroemer G, Sautès-Fridman C, Cremer I. (2016) Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis. *Cancer Res.* 76 : 1746-56. PMID: 26842877. IF=8.5
12. Dajon M, Iribarren K, Cremer I. (2016) Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword. *Immunobiology.* Jun 14. pii: S0171-2985(16)30096-1. Review. PMID: 27349597
13. Bruhns P, Teillaud JL. (2016) Inhibitory IgG Receptor-Expressing Cells: The Must-Have Accessory for Anti-CD40 Immunomodulatory mAb Efficacy. *Cancer Cell.* 29(6):771-3. PMID: 27300429.
14. Sautès-Fridman C, Lawand M, Giraldo NA, Kaplon H, Germain C, Fridman WH, Dieu-Nosjean MC. (2016) Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention. *Front Immunol.* 7:407. Review. PMID: 27752258.
15. Fridman WH. (2016) Historique de l'immunothérapie. Changement de paradigme ? *Bull Cancer.* 103 Suppl 1:S122-S126. PMID: 28057174.
16. ■ Vacchelli E, Bloy N, Aranda F, Buqué A, Cremer I, Demaria S, Eggermont A, Formenti SC, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. (2016) Trial Watch: Immunotherapy plus radiation therapy for oncological indications. *Oncoimmunology.* 5(9):e1214790. Review. PMID: 27757313.
17. Buqué A, Bloy N, Aranda F, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. (2016) Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. *Oncoimmunology.* Mar 10;5(6):e1149674. eCollection 2016 Jun.

- Review. PMID: 27471617.
18. Iribarren K, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Špišek R, Zitvogel L, Kroemer G, Galluzzi L. (2016) Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. *Oncoimmunology*. 5(3):e1088631. Review. PMID: 27141345
  19. Pol J, Buqué A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, Preville X, Sautès-Fridman C, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. (2016) Trial Watch-Oncolytic viruses and cancer therapy. *Oncoimmunology*. 5(2):e1117740. Review. PMID: 27057469
  20. Vacchelli E, Aranda F, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. (2016) Trial Watch-Immunostimulation with cytokines in cancer therapy. *Oncoimmunology*. 5(2):e1115942. Review. PMID: 27057468
  21. Fridman WH. (2016) [History of immunotherapy. Paradigm change?] *Bull Cancer*. pii: S0007-4551(16)00034-5. Review. French. PMID: 26976507
  22. Teillaud JL. (2016) [The man who blew-up the lock of the anti-tumor adaptive immune response]. *Med Sci (Paris)*. 32:121-2.
  23. Sautès-Fridman C, Fridman WH. (2016) TLS in Tumors: What Lies Within. *Trends Immunol*. 37:1-2. PMID: 26706045

#### 2016 - Fremeaux-Bacchi

24. ■ Roumenina, L. T., Rayes, J., Frimat, M., and Fremeaux-Bacchi, V. (2016) Endothelial cells: source, barrier, and target of defensive mediators, *Immunological reviews* 274, 307-329.
25. ■ Roumenina, L. T., Rayes, J., Lacroix-Desmazes, S., and Dimitrov, J. D. (2016) Heme: Modulator of Plasma Systems in Hemolytic Diseases, *Trends in molecular medicine* 22, 200-213.
26. Durey MA, Sinha A, Togarsimalemath SK, Bagga A. (2016) Anti-complement-factor H-associated glomerulopathies., *Nat Rev Nephrol*. 12(9):563-78
27. Loirat, C., Fakhouri, F., Ariceta, G., Besbas, N., Bitzan, M., Bjerre, A., Coppo, R., Emma, F., Johnson, S., Karpman, D., Landau, D., Langman, C. B., Lapeyraque, A. L., Licht, C., Nester, C., Pecoraro, C., Riedl, M., van de Kar, N. C., Van de Walle, J., Vivarelli, M., Fremeaux-Bacchi, V., and International, H. U. S. (2016) An international consensus approach to the management of atypical hemolytic uremic syndrome in children, *Pediatric nephrology* 31, 15-39.
28. Vieira-Martins, P., El Sissy, C., Bordereau, P., Gruber, A., Rosain, J., and Fremeaux-Bacchi, V. (2016) Defining the genetics of thrombotic microangiopathies, *Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis* 54, 212-219.

#### 2015 - Team Cremer/ Teillaud

29. Dajon M, Iribarren K, Cremer I. (2015) Dual roles of TLR7 in the lung cancer microenvironment. *Oncoimmunology*. 4(3):e991615. PMID: 25949912
30. Becht E, Giraldo NA, Beuselinck B, Job S, Marisa L, Vano Y, Oudard S, Zucman-Rossi J, Laurent-Puig P, Sautès-Fridman C, de Reyniès A, Fridman WH. (2015) Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). *Oncoimmunology*. 4(12):e1049804. PMID: 26587318
31. ■ Teng MW, Galon J, Fridman WH, Smyth MJ. (2015) From mice to humans: developments in cancer immunoediting. *J Clin Invest*. 125:3338-46. Review. PMID: 26241053
32. ■ Kroemer G, Galluzzi L, Zitvogel L, Fridman WH. (2015) Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy? *Oncoimmunology*. 4:e1058597. PMID: 26140250
33. Giraldo NA, Becht E, Vano Y, Sautès-Fridman C, Fridman WH. (2015) The immune response in cancer: from immunology to pathology to immunotherapy. *Virchows Arch*. 467:127-35. Review. PMID: 26077464
34. Teillaud JL. (2015) [When antibodies meet anti-tumor immunity: end of the game for tumor cells?]. *Med Sci (Paris)*. 31:707-8. PMID: 26340822
35. Bouvier M, Chneiweiss H, Jordan B, Lagrue G, Ménard J, Teillaud JL, Kroemer G, Moulin AM, Flahault A, Lafanechère L, Maréchal É, Guillemot JC, Gaille M. (2015) [The 2010 years]. *Med Sci (Paris)*. Spec No 1:91-111. PMID: 26038813
36. Beuselinck B, Fridman WH, Zucman-Rossi J. (2015) Molecular subtypes and prognosis in RCC. *Aging (Albany NY)*. 7:219-20. PMID: 25885644
37. ■ Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. (2015) Trial watch: Naked and vectored DNA-based anticancer vaccines. *Oncoimmunology*. 2;4(5):e1026531. PMID: 26155408



38. ■ Pol J, Bloy N, Buqué A, Eggermont A, Cremer I, Sautès-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. (2015) Trial Watch: Peptide-based anticancer vaccines. *Oncoimmunology*. 4(4):e974411. Review. PMID: 26137405
39. ■ Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. (2015) Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. *Oncoimmunology*. 4(4):e1008866. Review. PMID: 26137404
40. ■ Buqué A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. (2015) Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. *Oncoimmunology*. 4(4):e1008814. Review. PMID: 26137403
41. ■ Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L. (2015) Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. *Oncoimmunology*. 4(1):e985940. Review. PMID: 25949870
42. Zhu W, Germain C, Liu Z, Sebastian Y, Devi P, Knockaert S, Brohawn P, Lehmann K, Damotte D, Validire P, Yao Y, Valge-Archer V, Hammond SA, Dieu-Nosjean MC, Higgs BW. (2015) A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4<sub>T</sub> cell receptor repertoire clonality. *Oncoimmunology*. 4(12):e1051922. PMID: 26587322
43. Germain C, Gnjatic S, Dieu-Nosjean MC. (2015) Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity. *Front Immunol*. 6:67. Review. PMID: 25755654
44. Germain C, Gnjatic S, Dieu-Nosjean MC. (2015). Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity. *Front Immunol*. 6:67. PMID: 25755654
45. ■ Aranda F, Buqué A, Bloy N, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. (2015) Trial Watch: Adoptive cell transfer for oncological indications. *Oncoimmunology*. 4(11):e1046673. Review. PMID: 26451319
46. ■ Fucikova J, Moserova I, Urbanova L, Bezu L, Kepp O, Cremer I, Salek C, Strnad P, Kroemer G, Galluzzi L, Spisek R. (2015) Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. *Front Immunol*. 6:402. Review. PMID: 26300886
47. Sautès-Fridman C. (2015). Tumor Immunology, toward a Success Story? *Front Immunol*. 6:65. PMID: 25741340

#### 2015 - Fremeaux-Bacchi

48. Merle, NS, Church, SE, Fremeaux-Bacchi, V, Roumenina, LT: Complement System Part I - Molecular Mechanisms of Activation and Regulation. *Frontiers in immunology*, 6: 262, 2015.
49. Merle, NS, Noe, R, Halbwachs-Mecarelli, L, Fremeaux-Bacchi, V, Roumenina, LT: Complement System Part II: Role in Immunity. *Frontiers in immunology*, 6: 257, 2015.
50. Zipfel, PF, Skerka, C, Chen, Q, Wiech, T, Goodship, T, Johnson, S, Fremeaux-Bacchi, V, Nester, C, de Cordoba, SR, Noris, M, Pickering, M, Smith, R: The role of complement in C3 glomerulopathy. *Molecular immunology*, 67: 21-30, 2015.
51. Roumenina, LT: C3dg-CR3 interaction in erythrophagocytosis. *Blood*, 126: 828-829, 2015.
52. de Marcellus, C, Taha, MK, Gaudelus, J, Fremeaux-Bacchi, V, de Pontual, L, Guiddir, T: [Complement terminal fraction deficiency revealed at first invasive meningococcal infection]. *Archives de pediatrie : organe officiel de la Societe francaise de pediatrie*, 22: 296-299, 2015.
53. Fremeaux-Bacchi, V, Legendre, CM: The emerging role of complement inhibitors in transplantation. *Kidney international*, 88: 967-973, 2015.
54. Maillard, N, Wyatt, RJ, Julian, BA, Kiryluk, K, Gharavi, A, Fremeaux-Bacchi, V, Novak, J: Current Understanding of the Role of Complement in IgA Nephropathy. *Journal of the American Society of Nephrology : JASN*, 26: 1503-1512, 2015.

#### 2015 - Team Cremer/ Teillaud

55. Giraldo NA, Becht E, Remark R, Damotte D, Sautès-Fridman C, Fridman WH. (2014). The immune contexture of primary and metastatic human tumours. *Curr Opin Immunol*. 27:8-15. PMID: 24487185
56. Dieu-Nosjean MC, Goc J, Giraldo NA, Sautès-Fridman C, Fridman WH. (2014). Tertiary lymphoid structures in cancer and beyond. *Trends Immunol*. 35:571-80. PMID: 25443495
57. Alifano M, Mansuet-Lupo A, Lococo F, Roche N, Bobbio A, Canny E, Schussler O, Dermine H, Régnard JF, Burroni B, Goc J, Biton J, Ouakrim H, Cremer I, Dieu-Nosjean MC, Damotte D. (2014). Systemic

- inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancer. *PLoS One*. 9:e106914. PMID: 25238252
58. [Becht E, Goc J, Germain C, Giraldo NA, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH.](#) (2014). Shaping of an effective immune microenvironment to and by cancer cells. *Cancer Immunol Immunother*. 63:991-7. PMID: 25112529
  59. [Goc J, Fridman WH, Hammond SA, Sautès-Fridman C, Dieu-Nosjean MC.](#) (2014). Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses. *Oncoimmunology*. 3:e28976. PMID: 25083325
  60. [Fridman WH, Remark R, Goc J, Giraldo NA, Becht E, Hammond SA, Damotte D, Dieu-Nosjean MC, Sautès-Fridman C.](#) (2014). The immune microenvironment: a major player in human cancers. *Int Arch Allergy Immunol*. 164:13-26. PMID: 24852691
  61. [Fridman WH, Sautès-Fridman C.](#) (2014). The tumoral microenvironment: feeding resources, battle field and therapeutic target in cancer. *Med Sci (Paris)*. 30:359-65. PMID: 24801028
  62. [Sautès-Fridman C, Erdei A.](#) (2014). EFIS: driving women's representation in immunology in Europe. *Eur J Immunol*. 44:615. PMID: 24634268
  63. ■ [Teillaud JL, Kroemer G.](#) (2014). Cancer cells and their environments: friends and foes. *Med Sci (Paris)*. 30:343-4. PMID: 24801022
  64. ■ [Bouhlal H, Martinvalet D, Teillaud JL, Fridman C, Kazatchkine MD, Bayry J, Lacroix-Desmazes S, Kaveri SV.](#) (2014). Natural autoantibodies to Fcγ receptors in intravenous immunoglobulins. *J Clin Immunol*. 34 Suppl 1:S4-11. PMID: 24682714
  65. ■ [Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L.](#) (2014). Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. *Oncoimmunology*. 3:e27048. PMID: 24605265
  66. ■ [Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L.](#) (2014). Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. *Oncoimmunology*. 3:e27297. PMID: 24701370
  67. ■ [Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.](#) (2014). Classification of current anticancer immunotherapies. *Oncotarget*. 5:12472-508. PMID: 25537519
  68. ■ [Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, Erbs P, Limacher JM, Preville X, Zitvogel L, Kroemer G, Galluzzi L.](#) (2014). Trial Watch: Oncolytic viruses for cancer therapy. *Oncoimmunology*. 3:e28694. PMID: 25097804
  69. ■ [Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Henrik Ter Meulen J, Zitvogel L, Kroemer G, Galluzzi L.](#) (2014). Trial Watch: Toll-like receptor agonists in oncological indications. *Oncoimmunology*. 3:e29179. PMID: 25083332
  70. ■ [Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, Kroemer G, Galluzzi L.](#) (2014). Trial watch: Immunostimulatory cytokines in cancer therapy. *Oncoimmunology*. 3:e29030. PMID: 25083328
  71. ■ [Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Hervé Fridman W, Cremer I, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.](#) (2014). Trial Watch: Adoptive cell transfer for anticancer immunotherapy. *Oncoimmunology*. 3:e28344. PMID: 25050207
  72. ■ [Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Hervé Fridman W, Cremer I, Zitvogel L, Kroemer G, Galluzzi L.](#) (2014). Trial Watch: DNA vaccines for cancer therapy. *Oncoimmunology*. 3:e28185. PMID: 24800178
  73. ■ [Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Zitvogel L, Kroemer G, Galluzzi L.](#) (2014). Trial Watch: Chemotherapy with immunogenic cell death inducers. *Oncoimmunology*. 3:e27878. PMID: 24800173

#### 2014 - Fremeaux-Bacchi

74. [Loirat, C, Fremeaux-Bacchi, V:](#) Anti-factor H autoantibody-associated hemolytic uremic syndrome: the earlier diagnosed and treated, the better. *Kidney international*, 85: 1019-1022, 2014.
75. [Bagga, A, Sinha, A, Dragon-Durey, MA:](#) Therapy for patients with antibodies to complement factor H associated HUS. *Pediatric nephrology*, 29: 939-940, 2014.

76. Chauvet, S, Servais, A, Fremaux-Bacchi, V: [C3 glomerulopathy]. *Nephrologie & thérapeutique*, 10: 78-85, 2014.
77. Favre, GA, Touzot, M, Fremaux-Bacchi, V, Hyvernats, H, Gueffet, JP, Rohrlach, PS, Queyrel, V, Esnault, V, Fakhouri, F: Malignancy and thrombotic microangiopathy or atypical haemolytic and uraemic syndrome? *British journal of haematology*, 166: 802-805, 2014.
78. Rosain, J, Ngo, S, Bordereau, P, Poulain, N, Roncelin, S, Vieira Martins, P, Dragon-Durey, MA, Fremaux-Bacchi, V: [Complement deficiencies and human diseases]. *Annales de biologie clinique*, 72: 271-280, 2014.

#### 2013 - Team Cremer/ Teillaud

79. Goc J, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC. (2013). Characteristics of tertiary lymphoid structures in primary cancers. *Oncoimmunology*. 2:e26836. PMID: 24498556
80. Fridman WH, Dieu-Nosjean MC, Pagès F, Cremer I, Damotte D, Sautès-Fridman C, Galon J. (2013). The immune microenvironment of human tumors: general significance and clinical impact. *Cancer Microenviron*. 6:117-22. PMID: 23108700
81. Deligne C, Teillaud JL. (2013). The Janus face of monoclonal antibodies in oncology: passive immunity and vaccination. *Med Sci (Paris)*. 29:57-63. PMID: 23351695
82. ■ Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fučíková J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. (2013). Trial watch: Dendritic cell-based interventions for cancer therapy. *Oncoimmunology*. 2:e25771. PMID: 24286020
83. ■ Aranda F, Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. (2013). Trial Watch: Peptide vaccines in cancer therapy. *Oncoimmunology*. 2:e26621. PMID: 24498550
84. ■ Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. (2013). Trial Watch: Anticancer radioimmunotherapy. *Oncoimmunology*. 2:e25595. PMID: 24319634
85. ■ Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. (2013). Trial Watch: Toll-like receptor agonists for cancer therapy. *Oncoimmunology*. 2:e25238. PMID: 24083080
86. ■ Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. (2013). Trial watch: Oncolytic viruses for cancer therapy. *Oncoimmunology*. 2:e24612. PMID: 23894720
87. Stakhovsky O, Sanchez-Salas R, Barret E, Yap SA, Finelli A, Rozet F, Galiano M, Lenoir S, Strauss C, Validire P, Cathelineau X. (2013). Renal biopsies for small renal masses. For whom, when and how. *Arch Esp Urol*. 66:4-15. PMID: 23406796
88. Alifano M, Damotte D. (2013). Prognostic value of LIPC in non-small cell lung carcinoma. *Cell Cycle*. 12:543-4. PMID: 23370388
89. ■ Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. (2013). Trial Watch: Immunostimulatory cytokines. *Oncoimmunology*. 2:e24850. PMID: 24073369
90. ■ Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. (2013). Trial Watch: Adoptive cell transfer for anticancer immunotherapy. *Oncoimmunology*. 2:e24238. PMID: 23762803
91. ■ Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. (2013). Trial watch: DNA vaccines for cancer therapy. *Oncoimmunology*. 2:e23803. PMID: 23734328
92. Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. (2013). Trial watch: Chemotherapy with immunogenic cell death inducers. *Oncoimmunology*. 2:e23510. PMID: 23687621
93. Sandoval F, Terme M, Nizard M, Badoual C, Bureau MF, Freyburger L, Clement O, Marcheteau E, Gey A, Fraise G, Bouguin C, Merillon N, Dransart E, Tran T, Quintin-Colonna F, Autret G, Thiebaud M, Suleman M, Riffault S, Wu TC, Launay O, Danel C, Taieb J, Richardson J, Zitvogel L, Fridman WH, Johannes L, Tartour E. (2013). Mucosal imprinting of vaccine-induced CD8<sup>+</sup> T cells is crucial to inhibit the growth of mucosal tumors. *Sci Transl Med*. 5:172ra20. PMID: 23408053
94. Terme M, Fridman WH, Tartour E. (2013). NK cells from pleural effusions are potent antitumor effector cells. *Eur J Immunol*. 43:331-4. PMID: 23322344
95. ■ Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. (2013). Trial watch: Monoclonal antibodies in cancer therapy. *Oncoimmunology*. 2:e22789. PMID: 23482847

#### 2013 - Fremaux-Bacchi

96. Roumenina, LT, Zuber, J, Fremaux-Bacchi, V: Physiological and therapeutic complement regulators in kidney transplantation. *Current opinion in organ transplantation*, 18: 421-429, 2013.
97. ■ Dimitrov, JD, Planchais, C, Roumenina, LT, Vassilev, TL, Kaveri, SV, Lacroix-Desmazes, S: Antibody polyreactivity in health and disease: statu variabilis. *Journal of immunology*, 191: 993-999, 2013.

98. Skerka, C, Chen, Q, Fremaux-Bacchi, V, Roumenina, LT: Complement factor H related proteins (CFHRs). *Molecular immunology*, 56: 170-180, 2013.
99. Zuber, J, Le Quintrec, M, Morris, H, Fremaux-Bacchi, V, Loirat, C, Legendre, C: Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. *Transplantation reviews*, 27: 117-125, 2013.
100. Pickering, MC, D'Agati, VD, Nester, CM, Smith, RJ, Haas, M, Appel, GB, Alpers, CE, Bajema, IM, Bedrosian, C, Braun, M, Doyle, M, Fakhouri, F, Fervenza, FC, Fogo, AB, Fremaux-Bacchi, V, Gale, DP, Goicoechea de Jorge, E, Griffin, G, Harris, CL, Holers, VM, Johnson, S, Lavin, PJ, Medjeral-Thomas, N, Paul Morgan, B, Nast, CC, Noel, LH, Peters, DK, Rodriguez de Cordoba, S, Servais, A, Sethi, S, Song, WC, Tamburini, P, Thurman, JM, Zavros, M, Cook, HT: C3 glomerulopathy: consensus report. *Kidney international*, 84: 1079-1089, 2013
101. Servais, A, Noel, LH, Fremaux-Bacchi, V, Lesavre, P: C3 glomerulopathy. *Contributions to nephrology*, 181: 6.
102. Dragon-Durey, MA, Blanc, C, Marinozzi, MC, van Schaarenburg, RA, Trouw, LA: Autoantibodies against complement components and functional consequences. *Molecular immunology*, 56: 213-221, 2013.
103. Faguer, S, Huart, A, Fremaux-Bacchi, V, Ribes, D, Chauveau, D: Eculizumab and drug-induced haemolytic-uraemic syndrome. *Clinical kidney journal*, 6: 484-485, 2013.
104. Fakhouri, F, Fremaux-Bacchi, V: Thrombotic microangiopathy: eculizumab for atypical haemolytic uraemic syndrome: what next? *Nature reviews Nephrology*, 9: 495-496, 2013.
105. Fakhouri, F, Fremaux-Bacchi, V, Loirat, C: Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy. *European journal of internal medicine*, 24: 492-495, 2013.
106. Delmas, Y, Bordes, C, Loirat, C, Fremaux-Bacchi, V, Combe, C: Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice. *Clinical kidney journal*, 6: 243-244, 2013.
107. Loirat, C, Mariani-Kurkdjian, P, Fremaux-Bacchi, V: [Hemolytic uremic syndrome as of 2013]. *Archives de pediatrie : organe officiel de la Societe francaise de pediatrie*, 20: 827-830, 2013.
108. Fremaux-Bacchi, V: [Pathophysiology of atypical hemolytic uremic syndrome. Ten years of progress, from laboratory to patient]. *Biologie aujourd'hui*, 207: 231-240, 2013.

## 2012 - Team Cremer/ Teillaud

109. ■ Fridman WH, Pagès F, Sautès-Fridman C, Galon J. (2012). The immune contexture in human tumours: impact on clinical outcome. *Nat Rev Cancer*. 12:298-306. PMID: 22419253
110. Cremer I, Fridman WH, Sautès-Fridman C. (2012). Tumor microenvironment in NSCLC suppresses NK cells function. *Oncoimmunology*. 1:244-246. PMID: 22720258
111. Fridman WH. (2012). The immune microenvironment as a guide for cancer therapies. *Oncoimmunology*. 1:261-262. PMID: 22737600
112. Teillaud JL. (2012). From whole monoclonal antibodies to single domain antibodies: think small. *Methods Mol Biol*. 911:3-13. PMID: 22886242
113. Barrio MM, Abes R, Colombo M, Pizzurro G, Boix C, Roberti MP, Gélizé E, Rodriguez-Zubieta M, Mordoh J, Teillaud JL. (2012). Human macrophages and dendritic cells can equally present MART-1 antigen to CD8(+) T cells after phagocytosis of gamma-irradiated melanoma cells. *PLoS One*. 7:e40311. PMID: 22768350
114. Teillaud JL. (2012). Mix-up of Fc receptors in the response to monoclonal antibodies. *Med Sci (Paris)*. 28:11-3. PMID: 22289817
115. ■ Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. (2012). Trial watch: Peptide vaccines in cancer therapy. *Oncoimmunology*. 1:1557-1576. PMID: 23264902
116. ■ Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. (2012). Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. *Oncoimmunology*. 1:1323-1343. PMID: 23243596
117. ■ Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. (2012). Trial watch: Dendritic cell-based interventions for cancer therapy. *Oncoimmunology*. 1:1111-1134. PMID: 23170259
118. ■ Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. (2012). Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. *Oncoimmunology*. 1:894-907. PMID: 23162757

119. ■ Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. (2012). Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. *Oncoimmunology*. 1:699-716. PMID: 22934262
120. ■ Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. (2012). Trial Watch: Adoptive cell transfer immunotherapy. *Oncoimmunology*. 1:306-315. PMID: 22737606
121. ■ Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Kroemer G. (2012). Trial watch: Chemotherapy with immunogenic cell death inducers. *Oncoimmunology*. 1:179-188. PMID: 22720239
122. ■ Kroemer G, Fridman WH, Sautès-Fridman C, Zitvogel L. (2012). The European Academy of Tumor Immunology: Bridging fields, continents and generations. *Oncoimmunology*. 1:127-128. PMID: 22720233
123. ■ Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G. (2012). Trial Watch: Monoclonal antibodies in cancer therapy. *Oncoimmunology*. 1:28-37. PMID: 22720209
124. Cimino Y, Costes A, Damotte D, Validire P, Mistou S, Cagnard N, Alifano M, Régnard JF, Chiocchia G, Sautès-Fridman C, Tourneur L. (2012). FADD protein release mirrors the development and aggressiveness of human non-small cell lung cancer. *Br J Cancer*. 106:1989-96. PMID: 22669160
125. Galand C, Donnou S, Molina TJ, Fridman WH, Fisson S, Sautès-Fridman C. (2012). Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models. *Front Immunol*. 3:98. PMID: 22566974
126. Bouquet de Jolinière J, Ayoubi JM, Lescq G, Validire P, Goguin A, Gianaroli L, Dubuisson JB, Feki A, Gogusev J. (2012). Identification of displaced endometrial glands and embryonic duct remnants in female fetal reproductive tract: possible pathogenetic role in endometriotic and pelvic neoplastic processes. *Front Physiol*. 3:444. PMID: 23227010
127. Traibi A, Strauss C, Validire P, Gossot D. (2012). Intralobar pulmonary sequestration associated with bronchogenic cyst in adult. *Asian Cardiovasc Thorac Ann*. 20:597-9. PMID: 23087310
128. Favaretto RL, Ercolani MC, Sánchez-Salas R, Validire P, Barret E, Cathelineau X. (2012). Management of primary carcinoma of the seminal vesicle. *Actas Urol Esp*. 36:67-8. PMID: 21924524
129. Alifano M, Gaucher S, Rabbat A, Brandolini J, Guinet C, Damotte D, Regnard JF. (2012). Alternatives to resectional surgery for infectious disease of the lung: from embolization to thoracoplasty. *Thorac Surg Clin*. 22:413-29. PMID: 22789603
130. Donnou S, Galand C, Tuitou V, Sautès-Fridman C, Fabry Z, Fisson S. (2012). Murine models of B-cell lymphomas: promising tools for designing cancer therapies. *Adv Hematol*. 2012:701704. PMID: 22400032

## 2012 - Fremeaux-Bacchi

131. Zuber, J, Fakhouri, F, Roumenina, LT, Loirat, C, Fremeaux-Bacchi, V, French Study Group for a, HCG: Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. *Nature reviews Nephrology*, 8: 643-657, 2012.
132. Fakhouri, F, Vercel, C, Fremeaux-Bacchi, V: Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy. *Clinical journal of the American Society of Nephrology : CJASN*, 7: 2100-2106, 2012.
133. Fremeaux-Bacchi, V: Treatment of atypical uraemic syndrome in the era of eculizumab. *Clinical kidney journal*, 5: 4-6, 2012.
135. Malina, M, Roumenina, LT, Seeman, T, Le Quintrec, M, Dragon-Durey, MA, Schaefer, F, Fremeaux-Bacchi, V: Genetics of hemolytic uremic syndromes. *Presse medicale*, 41: e105-114, 2012.

Autres articles (articles publiés dans des revues professionnelles ou techniques, etc.)

### Equipe Complement and disease - V Fremeaux-Bacchi

#### 2016

Chyderiotid G, Dragon-Durey MA, Musset L, Fabien N. Maladie Coeliaque, Brochure EASI, Thermofisher Scientific, édition 2016

Chyderiotid G, Dragon-Durey MA, Musset L, Fabien N. Polyarthrite rhumatoïde, Brochure EASI, Thermofisher Scientific, édition 2016

#### 2013

Blanc C, Marinozzi MC, Bordereau P, Ngo S, Dragon-Durey MA. Auto-anticorps ciblant le complément: conséquences fonctionnelles et associations cliniques, *Spectra Biologica*, 2013.

## 2. Ouvrages

**Monographies et ouvrages scientifiques, éditions critiques, traductions****Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud****2017**

Damotte D. Bases fondamentales de l'immunothérapie (sous l'égide de la Société française du Cancer). Inflammation et cancer. Monographie de la revue Correspondances en Onco-Théranostic.

**2016**

Fridman WH. Historique de l'immunothérapie. Changement de paradigme ? Bull Cancer. 2016. 103 Suppl 1:S122-S126.

Ming Sun CM. Traduction : 1. The Vital Question par Nick Lane (Anglais à Chinois)

Mansuet-Lupo A. Hétérogénéité tumorale des adénocarcinomes du poumon, progression sous thérapie ciblée: exemple des mutations du récepteur à l' EGF. Correspondance en oncotheranostic.

**2014**

Fridman WH, Sautès-Fridman C. (2014). The tumoral microenvironment: feeding resources, battle field and therapeutic target in cancer. Med Sci (Paris). 2014. 30(4):359-65.

**2012**

Cremer I. Traduction française de cinq chapitres du livre « Immunology » 6<sup>th</sup> edition, Le cours de Janis Kuby de TJ Kindt, RA Golsby, BA Osborne. Edition DUNOD 2012.

**Equipe Complement and disease - V Fremeaux-Bacci****2014**

Dragon-Durey MA. Participation à la traduction de l'ouvrage : "Immunologie, le cours de Janis Kuby avec questions de révision" de T J Kindt, R A Golsby, B A Osborne, 7<sup>e</sup> édition, Edition DUNOD, Paris.

**Direction / édition scientifique**

Sautès-Fridman Catherine : direction de la traduction française du livre « Immunology » 6<sup>th</sup> edition, Le cours de Janis Kuby de TJ Kindt, RA Golsby, BA Osborne. Edition DUNOD 2012.

**Chapitres d'ouvrage****Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud****2017**

Alifano M, Bobbio A, Lorut C, Regnard JF. Thoracoplasty: Indications and Surgical Considerations. Shields's Textbook of Thoracic Surgery, 2017 Edition.

Bobbio A, Bertheloot L, Lupo A, Alifano M. Congenital Vascular Lesions of the Lungs. Shields's Textbook of Thoracic Surgery, 2017 Edition.

Bobbio A, Bertheloot L, Guinet C, Alifano M. Congenital Parenchymal Lesions of the Lungs. Shields's Textbook of Thoracic Surgery, 2017 Edition

Diane Damotte. Chapitre *Biomarqueurs prédictifs de l'immunothérapie* dans l'ouvrage Bases fondamentales de l'immunothérapie (sous l'égide de la Société française du Cancer), 2017.

Isabelle Cremer. Chapitre *Les récepteurs Toll-like : de la biologie au traitement* dans l'ouvrage Bases fondamentales de l'immunothérapie (sous l'égide de la Société française du Cancer), 2017.

Isabelle Cremer. Chapitre *Régulation de l'activation des cellules NK* dans l'ouvrage Bases fondamentales de l'immunothérapie (sous l'égide de la Société française du Cancer), 2017.

**2016**

Cremer I. Edition thérapie ciblée des cancers. Cibles épigénétiques. Chapitre 4 : Récepteurs Toll-like. 2016. Editions John Libbey Eurotext.

Becht E, Giraldo NA, Germain C, De Reyniès A, Laurent-Puig P, Zucman-Rossi J, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH. Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. Adv Immunol. 2016, 130:95-190.

Becht E, Giraldo NA, Germain C, De Reynies A, Laurent-Puig P, Zucman-Rossi J, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH. Chapter « Immune contexture, immunoscore and malignant cell molecular subgroups for prognostic and theranostic classifications of cancer ». Book « *Tumor Immunology* », Advances Immunol. edited by Dr. R.D. Schreiber, Elsevier Ed., 2016, 130:95-190. ISBN 978-0-12-805156-6.

Dubois B, Kaplon H, Couillaut C, Caux C, Dieu-Nosjean MC. Chapter « Cancer-associated tertiary lymphoid structures, from basic knowledge toward therapeutic target in clinic ». Book entitled « *Defects in T cell trafficking and resistance to cancer immunotherapy* » edited by Dr. E. Donnadieu. Series entitled « Resistance to targeted anti-cancer therapeutics ». Springer edition, 2016, p99-126, ISBN 978-3-319-42221-3.

**2015**

Sautès-Fridman C, Cremer I. Immunothérapie des cancers au 3<sup>ème</sup> millénaire. Chapitre 4 : Rôle pronostique des lymphocytes NK dans les cancers. 2015. Edp sciences.

**2014**

Deligne C, Siberil S, Teillaud JL. The vaccinal effect of monoclonal antibodies in cancer therapy. In “*Tumour Immunology and Immunotherapy*” (R.C. Reed, ed.), Oxford University Press, 2014, pp. 357-71.

Roumenina, LT, Roquigny, R, Blanc, C, Poulain, N, Ngo, S, Dragon-Durey, MA, Fremeaux-Bacchi, V: Functional evaluation of factor H genetic and acquired abnormalities: application for atypical hemolytic uremic syndrome (aHUS). *Methods in molecular biology*, 1100: 237-247, 2014.

Dragon-Durey, MA, Blanc, C, Roumenina, LT, Poulain, N, Ngo, S, Bordereau, P, Fremeaux-Bacchi, V: Anti-factor H autoantibodies assay. *Methods in molecular biology*, 1100: 249-256, 2014.

**2013**

Fridman WH, Dieu-Nosjean MC, Pages F, Cremer I, Damotte D, Sautès-Fridman C, Galon J. Chapter « The immune microenvironment of human tumors: general significance and clinical impact ». Book « *Cancer Microenvironment* » edited by Springer. 2013. 6(2): 117-22, ISSN 1875-2292.

Alifano M, Rabbat A, Tesnière A, Roche N. Antibiotic prophylaxis in lung resection surgery. European Respiratory Monograph: Complex pleuro-pulmonary infection, Chapter 1. Septembre 2013.

Rabbat A, Alifano M, Magro P. Diagnostic des pleurésies (hors cancer). La pneumologie fondée sur les preuves, Edition 2013, sous l’Egide de la SPLF, Ed.Lemarié E.

Rabbat A, Lemarié E, Fraticelli A, Alifano M. Pneumothorax spontané primitif. La pneumologie fondée sur le preuves, Edition 2013, sous l’Egide de la SPLF, Ed.Lemarié E.

Joubert PE. Cell surface pathogen receptor CD46 induces autophagy. Academic Press, Elsevier, e.d. M.A Hayat, 2013.

Fridman WH, Dieu-Nosjean MC, Pages F, Cremer I, Damotte D, Sautès-Fridman C, Galon J. Chapter « The immune microenvironment of human tumors: general significance and clinical impact ». Book « *Cancer Microenvironment* » edited by Springer, 2013, 6(2):117-22, ISSN 1875-2292.

**2012**

Bobbio A, Damotte D, Gompel A, Alifano M. Extra-abdominal endometriosis. In: *Endometriosis: Science and Practice*, First Edition. Edited by Linda C. Giudice, Johannes L.H. Evers and David L. Healy. Blackwell Publishing Ltd., 2012, chapter 10.

Donnou S, Galand C, Toutou V, Sautès-Fridman C, Fabry Z, Fisson S. Murine models of B-cell lymphomas: promising tools for designing cancer therapies. Adv Hematol. 2012, 701704.

**Equipe Complement and disease - V Fremeaux-Bacchi**

**2014**

Dragon-Durey MA. Coordonnatrice et rédactrice du chapitre « Immunologie humorale » du « Guide des analyses en Immunologie », ouvrage ASSIM. Edition Masson. 2014.

Dragon-Durey MA. Rédaction d’un chapitre de l’ouvrage « The Complement System, Methods and Protocols », Springer protocols, Editor M Gadjeva, Humana Press. 2014

Dragon-Durey MA. Rédaction des chapitres « Mécanismes physiopathologiques de l’auto-immunité » et « Le système du Complément » dans l’ouvrage de l’ASSIM, « Enseignement de l’Immunologie en L2/L3 ». Editions Masson. 2014

**2012**

Dragon-Durey MA. Rédaction du Chapitre "Le système du Complément", dans l’édition 2012 de l’ouvrage « l’Immunologie » des Pr F Bach et L Chatenoud. Editions Lavoisier.

**Thèses publiées / éditées**

*For the period 2012-2017 12 PhD students defended in the team Cremer/Teillaud and 7 in the team Fremeaux-Bacchi*

**Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud****2017**

Marion Dajon, Université Pierre et Marie Curie. Pro-tumoral role of TLR7 in Non-Small-Cell Lung Carcinoma (NSCLC): role of MDSC. Financement : allocation doctorale. Direction Cremer I.

Ludovic Fournel, Université Paris Descartes. La voie de signalisation neurotensinergique dans le cancer bronchique non à petites cellules: impact sur le microenvironnement immunitaire et la réponse au cisplatine» : en cours. Direction Alifano M.

**2016**

Estelle Devevre. Université Pierre et Marie Curie. Caractérisation des sous-populations de monocytes chez les patients obèses. Financement : Poste ingénieur d'études statutaire. Direction Cremer I.

**2015**

Nicolas Giraldo. Université Pierre et Marie Curie. The immune microenvironment in clear cell Renal Cell Cancers. Financement : allocation doctorale. Direction Sautès-Fridman C.

Etienne Becht. Université Paris Descartes. Analyse moléculaire et immunologique des cancers colorectaux. Financement : allocation doctorale. Direction Fridman WH.

Priyanka Devi. Université Pierre et Marie Curie. Rôle and pronostic importance of regulatory T cells in lung cancer patients according to the presence of tertiary lymphoid structures. Financement : bourse Erasmus mundus puis Fondation ARC (4<sup>ème</sup> année). Direction Dieu-Nosjean MC.

**2014**

Audrey Lupo. Université Paris Descartes. Influence des caractéristiques morphologiques et mutationnelles des carcinomes pulmonaires sur leur environnement immunitaire et leur pronostic. Direction Damotte D.

**2013**

Saradiya Chatterjee. Université Pierre et Marie Curie. Role of TLR7 in Non-Small-Cell Lung Carcinoma (NSCLC). Financement : Programme Erasmus Mundus. Direction Cremer I.

Romain Remark. Université Paris Descartes. Composition, organisation et impacts cliniques des microenvironnements immunitaires des tumeurs primitives et métastatiques. Financement : allocation doctorale. Direction Damotte D.

Mariette Baud. Université Paris Descartes. Biomarqueurs dans le mésothéliome pleural malin: expression de la neurotensine et du récepteur NTSR1. Direction Alifano M.

Ludovic Fournel. Thèse de doctorat en Médecine, diplôme d'Etat (Mr). Prise en charge chirurgicale des tumeurs neuroendocrines pulmonaires non à petites cellules. Direction Alifano M.

Jeremy Goc. Université Pierre et Marie Curie. Role des structures lymphoïdes tertiaires dans le recrutement et l'activation des lymphocytes T et valeur pronostique associée dans le cancer pulmonaire humain. Financement : allocation doctorale puis Fondation ARC (4<sup>ème</sup> année). Direction Dieu-Nosjean MC.

**Equipe Complement and disease - V Fremeaux-Bacchi****2017**

Nicolas Merle. Université Paris Descartes. Complement activation in hemolytic conditions. Direction Roumenina L., allocation doctorale

**2016**

Shambhuprasad Kotresh. Université Paris Descartes. Implication du facteur H et des CFHR dans les glomérulopathies à C3 et dans la forme autoimmune du syndrome hémolytique et urémique atypique. Direction Dragon-Durey MA., SEFIPRA fellowship



Maria-Chiara Marinozzi. Université Paris Descartes. Characterization of the complement hereditary and acquired abnormalities in atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. Direction Fremeaux-Bacchi V., EurReinOmix FP7 European grant

Sophie Chauvet. Université Paris Descartes. Rôle des facteurs génétiques et acquis dans la physiopathologie des glomérulopathies à dépôts de C3. Direction Fremeaux-Bacchi V., allocation doctorale FRM

### 2013

Marie Frimat. Université Paris Descartes. Lésions endothéliales liées à un défaut de contrôle du complément : de la génétique du complément au syndrome hémolytique et urémique. Direction Fremeaux-Bacchi V and Halbwegs-Mecarelli L.

Moglie Lequintrec. Université Paris Descartes. Facteurs prédictifs de récurrence et de sévérité du syndrome hémolytique et urémique atypique et de la glomérulonéphrite à C3 après transplantation rénale. Direction Fremeaux-Bacchi V.

### 2012

Caroline Blanc. Université Paris Descartes. Etude des auto-anticorps anti-Facteur H dans le Syndrome Hémolytique et Urémique atypique et dans la glomérulonéphrite membrano-proliférative. Direction Dragon-Durey MA, allocation doctorale

## 3. Colloques / congrès, séminaires de recherche

*The two teams presented more than 230 abstracts at international and national conferences, about 150 for the team Cremer/Teillaud and more than 80 for the team of Fremeaux-Bacchi.*

### Éditions d'actes de colloques / congrès

#### Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud

### 2016

Mansuet-Lupo A. La densité des lymphocytes T CD8+ et des cellules dendritiques matures intra-tumorales est associée à un profil d'altérations moléculaires dans les adénocarcinomes pulmonaires. Carrefour Pathologie, Paris. (national)

Mansuet-Lupo A. Classification anatomo-pathologique : impact au quotidien. 10<sup>ème</sup> réunion clinico-pathologique en oncologie thoracique. Groupe Français de Pneumo-Cancérologie. Paris. (national)

Mansuet-Lupo A. Tumeur neuroendocrine du poumon : diagnostic sur cytologie/microbiopsie - Recommandations de la classification OMS 2015. Symposium SFCC/SFP. Carrefour pathologie, Paris. (national)

Mansuet-Lupo A. Actualité des tumeurs pleurales : corrélations radio-histologique et nouveaux marqueurs diagnostiques. Journée Française de Radiologie, Paris. (national)

Mansuet-Lupo A. Endométriose thoracique : manifestations cliniques et aspect anatomo-pathologiques. Hôpital St Joseph, Paris. (national)

Mansuet-Lupo A. Analyse de l'axe PD-L1/PD-1 en pathologie. Réunions Oncomolpath 8<sup>ème</sup> édition, Paris.

Mansuet-Lupo A. Sous-types histologiques des adénocarcinomes, phénotype moléculaire et micro-environnement : une synthèse des interrelations. 8<sup>ème</sup> congrès génération thorax, Nice. (national)

Mansuet-Lupo A. Statut immunohistochimique PD-L1 dans les carcinomes pulmonaires. 6<sup>ème</sup> Journée des pathologistes des CHG, Paris. (national)

#### Equipe Complement and disease - V Fremeaux-Bacchi

### Articles publiés dans des actes de colloques / congrès

#### Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud

The team has submitted more than 150 abstracts in national and international meetings.

Deligne C, Siberil S, Teillaud JL. Anti-CD20 therapy prevents protumor regulatory T-cell expansion and triggers a memory Th1 response in tumor-bearing mice. *Cancer Res.*, 2014, 74(19 Suppl.):3636 (abstract). doi: 10.1158/1538-7445.AM2014-3636. AACR Annual Meeting 2014; April 5-9, 2014; San Diego (USA).

Dieu-Nosjean MC, Goc J, Germain C, Knockaert S, Alifano M, Lupo A, Damotte D, Validire P, Hammond SA, Fridman WH, Sautès-Fridman C. Prognostic importance of both stage of the disease and immune infiltrate in the outcome of NSCLC patients. *Cancer Res.*, 2014, 74(19 Suppl):1650 (abstract). DOI: 10.1158/1538-7445.AM2014-1650. AACR Annual Meeting 2014; April 5-9, 2014; San Diego (USA).

Devi P, Goc J, Germain C, Knockaert S, Validire P, Damotte D, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC. Identity card of tumor-infiltrating regulatory T cells in the context of tertiary lymphoid structures in lung cancer patients. *Cancer Res.*, 2016, 76(14 Suppl.): LB-273 (abstract). DOI: 10.1158/1538-7445.AM2016-LB-273. AACR Annual Meeting 2016; April 16-20, 2016 ; New Orléans (USA).

**Equipe Complement and disease - V Fremeaux-Bacci**

The team has submitted more than 50 abstracts in national and international meetings.

**Autres produits présentés dans des colloques / congrès et des séminaires de recherche**

**Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud**

**2016**

Teillaud JL, Annual Meeting of the French Society for Immunology, Paris (28-30 novembre 2016) (modérateur session "Anti-Tumor Immunity")

**2015**

Cremer I. TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer. European Congress in Immunology. Vienne, Autriche. Septembre 2015. Oral communication (international)

Dieu-Nosjean MC. Tertiary lymphoid structure-associated B cells are key players in anti-tumor immunity. « Therapeutic antibodies 2015: new trends in Oncology ». Groupement De Recherche (GDR) Antibody and Therapeutic Targeting (ACCITH) of CNRS, Institut Curie, Paris, France, November 12-13th, 2015. Oral communication (national)

**2014**

Dieu-Nosjean MC. Tertiary lymphoid structures in lung cancer patients : a major contributor to a beneficial immune microenvironment. Miltenyi Biotec EATI and SITC meeting « Natural and therapy-induced anticancer immunosurveillance : the immunoscore », Paris, France, July 3-4th, 2014. Oral communication (international)

Dieu-Nosjean MC. Tertiary lymphoid structures, as a new driver of a protective immune response in human lung cancer. Program ADELIH international congress, Paris, France, October 16-17th, 2014. Oral communication (international)

Dieu-Nosjean MC. (plenary session) Role of Tertiary lymphoid structures in the shaping of an efficient and beneficial immune reaction in lung cancer patients, 4<sup>th</sup> World Congress on « Cancer Science and Therapy », Chicago, USA, October 20-22th, 2014. Oral communication (international)

Joubert PE. 13<sup>th</sup> International symposium on Dendritique Cells, Tour, France, 2014. Unexpected role of mTORC1 on CHIKV replication. (national)

Joubert PE European Workshops on Cell Death, Monétier-les-bains, France. "Death à la carte". Chikungunya virus-induced autophagy delays apoptosis via the induction of ER stress and generation of reactive oxygen species, 2014 (national).

**2013**

Dieu-Nosjean MC. (plenary session) Good prognostic value of tertiary lymphoid structures in human lung cancer. EULAR - EFIS congress, Madrid (Spain), June 12-15th, 2013 Oral communication (international).

Goc J, De Chaisemartin L, Lupo A, Damotte D, Validire P, Vo-Bourgais D, Devi P, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC. Density of tertiary lymphoid structures predicts T cell infiltration with coordinated Th1 polarization and cytotoxic effector functions in human lung cancer. International Congress of Immunology, Milan, Italy, August 22-27th, 2013 Oral communication (international).

Dieu-Nosjean MC. (plenary session) Tertiary lymphoid structure, a link with cancer. Hay-day colloquium « Tertiary lymphoid system ». Paris, France, February 22th, 2013. Oral communication (national)

Dieu-Nosjean MC, Goc J, Vo-Bourgais D, Lupo A, Damotte D, Validire P, Fridman WH, Sautes-Fridman C. Tertiary lymphoid structure dendritic cells signal a Th1 and cytotoxic immune contexture, and are required for good prognostic value of CD8<sup>+</sup> T cells in lung cancer patients. Société Française d'Immunologie, Paris, November 4-7th, 2013. Oral communication (national)

**2012**

Cremer I. TLR7 in Non-Small-Cell Lung Carcinoma (NSCLC) patients: a double-edged sword. CSH Asia / ICMS. The International Cancer Microenvironment. Suzhou. Chine. Novembre 2012. Oral communication. (international)

Joubert PE Annual Conference of the European Academy of Tumor Immunology, Institut Pasteur. Chikungunya, cell stress and cell death, 2012 (national).

Joubert PE Conference of the European Research Institute for Integrated Cellular Pathology. Paris. Chikungunya, cell stress and cell death, 2012 (national).

#### **4. Développements instrumentaux et méthodologiques**

##### **Prototypes et démonstrateurs**

Sans objet

##### **Plateformes et observatoires**

Sans objet

#### **5. Produits et outils informatiques**

##### **Logiciels**

Sans objet

##### **Bases de données / cohortes**

###### **Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud**

Alifano M. Base prospective de cancers broncho-pulmonaires reséqués Hôpital Cochin de Paris 2017-

Alifano M. Base rétrospective de thymomes reséqués en 19 centres en Europe 2000-2017

Alifano M. Plusieurs bases rétrospectives nécessaires à la réalisation des études clinique citées en bibliographie

##### **Corpus**

Sans objet

##### **Outils présentés dans le cadre de compétitions de solveurs**

Sans objet

##### **Outils d'aide à la décision**

Sans objet

#### **6. Brevets, licences et déclarations d'invention**

*The teams filled 22 patents for the period 2012-2017*

**Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud****2017**

Damotte D. Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (NSCLC) that coexists with chronic obstructive pulmonary disease (COPD)". EP16305597.3 filed on 24 May 2016

**2016**

Methods or predicting the outcome of a patients by analysing gene expression 2016-230291. Galon J, Pages F, Mlecnik B, Fridman WH.

Methods for quantifying the proportion of myeloid dendritic cells in a tissue sample. Becht E, de Reynies A, Fridman WH, EP 16305889.4, 12 Juillet 2016

Cytotoxic antibody directed against Type B lymphoid hematopoietic proliferations. De Romeuf C, Gaucher C, Teillaud JL, Prost JF. US 2016/0060350 A1

Method for the prognosis of survival time of a patient suffering from a solid cancer. M.-C. Dieu-Nosjean, W. H. Fridman, J. Goc, C., Sautès-Fridman. US patent n° 14/905,177.

Method for predicting the survival time of patients suffering from a lung cancer. M.-C. Dieu-Nosjean, P. Devi, W. H. Fridman, C. Sautès-Fridman. EP 15306318.5

Methods for quantifying the proportion of myeloid dendritic cells in a tissue sample , E Becht, A de Reynies, WH Fridman, EP 16305889.4, 12 Juillet 2016

**2015**

Method for predicting the survival time of patients suffering from a lung cancer. European patent n° EP 15306318.5, (co-inventors: M.C. Dieu-Nosjean, P. Devi, W. H. Fridman, C. Sautès-Fridman), UMRS1138 INSERM, August 27th, 2015.

Production of Antibody Formats and immunological Applications of Said Formats. Baty D, Behar G, Chartier M, Pèlegri A, Teillaud JL, Teulon I. EP 1 824 884 B1.

Methods for quantifying the proportion of myeloid dendritic cells in a tissue sample, E Becht, A de Reynies, WH Fridman, EP 15306520.6 29.09.2015

Methods for quantifying the proportion of granulocytes in a tissue sample, E Becht, A de Reynies, WH Fridman EP 15306523.0 , 29.09. 2015

Methods for quantifying the proportion of T cells in a tissue sample, E Becht, A de Reynies, WH Fridman, EP15306519.8 , 29.09. 2015

Methods for quantifying the proportion of B cells in a tissue sample, E Becht, A de Reynies, WH Fridman, EP15306516.4 , 29.09. 2015

Gene signatures for the quantification of NK cells in a tissue sample, E Becht, A de Reynies, WH Fridman, EP15306523.0 , 29.09. 2015

**2014**

Cherfils-Vicini J, Fridman C, Cremer I, Methods for predicting the response to treatment and for treating cancer. EP14305317.1. INSERM. Mars 2014.

Fridman WH. Method for the prognosis of survival time of a patient suffering from a solid cancer". EP 12 151 875.7, UMRS872 INSERM, January 2012

Method for the prognosis of survival time of a patient suffering from a solid cancer. Dieu-Nosjean MC, Fridman WH, Goc J, Sautès-Fridman C. PCT/EP2014/064886

Method for the prognosis of survival time of a patient suffering from a solid cancer. Dieu-Nosjean MC, Fridman WH, Remark R, Sautès-Fridman C. Jpn patent n° 2014-552651

**2013**

Method for the prognosis of survival time of a patient suffering from a solid cancer. Dieu-Nosjean MC, Fridman WH, Goc J, Sautès-Fridman C. EP 13306004.6

**Equipe Complement and disease - V Frémeaux-Bacchi****2015**

M-C Marinozzi, L.T. Roumenina, V Frémeaux-Bacchi, Polypeptides for the diagnosis and treatment of C3 NeF associated C3 Glomerulopathy, European patent application EP15305952

**2013**

Dragon-Durey MA. Dépôt de Brevet en Septembre 2013, sous l'égide de INSERM Transfert Patent N° 13306251.3-1405. Dépôt international en Avril 2015. Repris par l'APHP en Mars 2017.

## 7. Rapports d'expertises techniques, produits des instances de normalisation

### Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud

Alifano M.

2013 et 2016 Co-rédacteur du référentiel d'Oncologie Thoracique du G.H.

2014-2016 Coordonnateur du projet d'acquisition d'un robot chirurgical pour les Hôpitaux Universitaires Paris-Centre

2015-2016 Coordonnateur du projet « Innovations et Technologie » du projet de construction de la Plateforme Médico-Chirurgicale et des Urgences (PMCU) des Hôpitaux Universitaires Paris-Centre

2016-2017 Coordonnateur du projet médical de la Plateforme Médico-Chirurgicale et des Urgences des Hôpitaux Universitaires Paris-Centre

2017 Membre du COPIL Chirurgie du Programme régional de santé de l'ARS Ile de France

## 8. Produits des activités didactiques

### Ouvrages

### Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud

2016

Teillaud JL. Intervention orale à l'Ouverture des Journées nationales de l'APBG (Association des Professeurs de Biologie et de Géologie), Faculté de Médecine site des Saints-Pères, Université Paris-Descartes (18 novembre 2016)

2015

Teillaud JL. International School of Immunological Therapies : Concepts and Development (IBCD) [Université Pierre & Marie Curie (UPMC-Mount Sinai School of Medicine (New York, Etats-Unis)- Universidade de Sao Paulo, Brésil] (21 Septembre 2015)

2014

Sautès-Fridman C. Direction de la traduction de la 7<sup>ième</sup> édition du livre « Immunologie » Kuby, 2014 paru chez Dunod

Teillaud JL. Représentation du Centre de Recherche des Cordeliers à l'inauguration des expositions de l'Ecole Nationale Supérieure de la Photographie (Arles) (8 Juillet 2014)

2013

Alifano M. Les interventions chirurgicales sur le poumon. Lettre du souffle N. 72, Novembre 2013

### E-learning, moocs, cours multimedia, etc.

### Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud

2016

Alifano M. Experts' meeting Vidéoconference from general thoracic surgery, 'San Paolo' hospital - Bari, Catamenial pneumothorax. 4 juillet 2016, Bari, Italie.

Fridman WH. DU-thérapeutiques Immunologiques sur le web

Sibénil S. dans le cadre de la formation continue UPMC, réalisation d'une vidéo destinée au E-learning : "Les anticorps thérapeutiques" 2016-2017.

### Equipe Complement and disease - V Frémeaux-Bacchi

2016

Roumenina L. Complement system, module for the MOOC Innate immunity and infectious diseases, Institute Pasteur

## 9. Produits destinés au grand public

### Émissions radio, TV, presse écrite

Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud

2017

Alifano M. « Un bloc Opérateur modulaire » LCI le 20/05/2017

### Produits de vulgarisation : articles, interviews, éditions, vidéos, etc.

Sans objet

### Produits de médiation scientifique

Sans objet

### Débats science et société

Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud

2016

Teillaud JL. Intervention orale à l'Ouverture des Journées nationales de l'APBG (Association des Professeurs de Biologie et de Géologie), Faculté de Médecine site des Saints-Pères, Université Paris-Descartes (18 novembre 2016)

2014

Teillaud JL. Représentation du Centre de Recherche des Cordeliers à l'inauguration des expositions de l'École Nationale Supérieure de la Photographie (Arles) (8 Juillet 2014)

Teillaud, JL. Mort de Julius Axelrod. *Encyclopædia Universalis*, La Science au présent 2014, 2014, pp. 268-9.

2012

Sautès-Fridman C. Organisation de sessions « Women in Science » lors des congrès européens et internationaux d'immunologie (ECI2012, ECI2015, FIMSA 2012)

## 10. Autres produits propres à une discipline

### Créations artistiques théorisées

Sans objet

### Mises en scènes

Sans objet

### Films

Sans objet

## II. ACTIVITÉS DE RECHERCHE ET INDICES DE RECONNAISSANCE

*La liste de ces activités n'a pas à être exhaustive. On mettra en évidence les activités les plus significatives en termes de rayonnement et d'attractivité, d'interaction avec l'environnement et d'implication dans la formation par la recherche.*

## 1. Activités éditoriales

Teams members participate as editors in international journals such as *Cancer immunology research*, *Frontiers in Immunology* (3x), *Mabs*, *Human antibodies* as well as in the French journals *Médecine/Sciences* and *Immunité et Cancer*.

### Participation à des comités éditoriaux (revues, collections)

#### Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud

Fridman WH. *Cancer Immunology Research*, membre de l'éditorial board

Teillaud JL. Membre du Comité Editorial du journal "mAbs" (depuis son lancement en Janvier 2009)

Teillaud JL. Membre du Comité Editorial du journal "Médecine/Sciences (depuis Janvier 2011)

Teillaud JL. Membre du comité éditorial du journal « Human Antibodies » (depuis Janvier 2012)

Teillaud JL. Editeur en chef de « *Frontiers in Immunotherapies and Vaccines* » (2011-2015) (Frontiers Specialty Chief Editor)

Teillaud JL. **Rédacteur en chef** de la revue de l'INSERM « *Médecine / Sciences* » (depuis 1<sup>er</sup> Janvier 2017).

Teillaud JL. Editeur invité pour la réalisation du numéro spécial de *Médecine / Sciences* « Micro-environnement tumoraux : conflictuels et complémentaires », [Med Sci (Paris), 2014, 30 ; doi: 10.1051/medsci/20143004001 (avec le Dr. L. Coulombel).

Teillaud JL. Editeur invité pour la réalisation du numéro spécial de *Médecine / Sciences* « Le microbiote : cet inconnu qui nous habite ». [Med Sci (Paris), 2016, 32. doi: 10.1051/medsci/20163211002] (avec le Dr. H. Gilgenkranz).

#### Equipe Complement and disease - V Frémeaux-Bacchi

Roumenina L. Review editor for *Frontiers in Immunology*, *Innate immunity*

### Direction de collections et de séries

#### Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud

Sautés-Fridman C. Rédactrice en chef de la section « *Cancer Immunity and immunotherapy* » de la revue « *Frontiers in Immunology* », IF = 6.9; depuis 2015

Rédactrice en chef de la revue '*Immunité et Cancer* », 4 numéros/an créée en 2016

Fridman WH. Créateur et Rédacteur en chef de la section « *Cancer Immunity and immunotherapy* » de la revue « *Frontiers in Immunology* », 2012-2015

## 2. Activités d'évaluation

Members of the two teams participated in evaluation instances at international level, such as: ERC advanced grant panel (WH Fridman), ERC consolidator grant panel (C. Sautés-Fridman), panel memberships for national grant funding institutions in Finland, The Netherlands (C. Sautés-Fridman), and Hungary (L. Roumenina). Different members of the teams are also reviewers for grant applications for 19 different grant funding organizations in Europe, North and South America.

Team members are as well as for over 80 different journals, including *NEJM*, *Nature*, *Nat Rev Immunol*, *JCI*, *Sci Transl Med*, *Blood*, *J Clin Oncol*, *Cancer res*, *JASN*, *Kidney Int*.

The notoriety of the two team is also evident at national level, where members hold key positions such as: director of UPMC doctoral school "Physiology, physiopathology and therapeutics" (I. Cremer), director of the scientific commission of the French Nephrology society (V. Frémeaux-Bacchi), evaluator for HCERES (I. Cremer, D. Damotte), members of UPMC administrative and scientific council (I. Cremer, MC Dieu-Nosjean), members of

scientific commission "Cell interactions" in CNRS (MC. Dieu-Nosjean), members of panels for grants evaluation in La Ligue contre le cancer (I. Cremer) or Fondation ARC (JL Teillaud and MC Dieu-Nosjean).

### Responsabilités au sein d'instances d'évaluation

#### Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud

Alifano M. 2011- Membre de la commission des Effectifs, vice président de la commission des structure, membre élu à la CMELHôpitaux Universitaires Paris centre

Damotte D. - vice président de la commission des effectifs, membre de la commission des structures, membre élu de la CMEL Hôpitaux Universitaire Paris Centre ; Membre du comité d'audition hospitalo-universitaire faculté de médecine Paris Descartes. Responsable de l'enseignement de la pathologie thoracique au DES de pathologie.

Cremer I. **Directrice de l'Ecole Doctorale Physiologie, Physiopathologie et Thérapeutique (ED394, Université Paris 6); membre de la commission 2 « Immunologie, Hématologie » de la Ligue contre le cancer** (depuis mars 2017); membre du groupe d'experts pour les jury de concours MCU et PU (Université Paris 6); membre du conseil d'administration et du conseil scientifique de l'UFR927 Sciences de la vie, Université Paris 6.

Sautès-Fridman C. Membre du BIO2 panel, Académie de Finlande, Helsinki, 2016 ; membre du Gravitation panel comité de la NWO, Amsterdam, 2016

Fridman WH. Membre du panel Advanced grants de l'ERC de 2008-2015

Teillaud JL. Membre de la Commission Nationale 1 (CN1) de la Fondation ARC (2014-2016).

Dieu-Nosjean MC. Membre de la Commission Nationale « Immunologie, Oncohématologie, Microbiologie » (CN1) de la Fondation ARC depuis 2017.

Sibénil S. Membre du jury d'attribution des allocations doctorales de l'ED BioSPC (Bio Sorbonne Paris Cité)

#### Equipe Complement and disease - V Frémeaux-Bacchi

Dragon-Durey MA. Membre du jury du comité de sélection de MCU (Universités Paris Descartes, Pierre et Marie Curie et Angers) ; membre du jury du Concours National de Praticien Hospitalier 2013-2014 (Présidente du comité N°2).

Roumenina L. Member of the Infraindividual Biology panel of the National Research, Development and Innovation Office, Hungary (2017); member of the jury for the evaluation of the PhD candidates for the doctoral school ED 394 - UPMC Sorbonne Universités, Physiology, Physiopathology and Therapeutics (2017)

### Évaluation d'articles et d'ouvrages scientifiques

Expertise régulière dans de nombreuses revues:

#### Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud

Cremer I. Cancer Research, Journal of Clinical Investigation, Plos one, Cancer Immunology Immunotherapy, European Journal of Immunology, Oncotarget, Oncoimmunology.

Mansuet-Lupo A. J Clin Pathol

Damotte D. Oncoimmunology, Lung cancer, Immunotherapy, New England Journal of Medicine, Journal of Biochemistry

Alifano M. Annals of Thoracic Surgery, European Journal of Cardio-Thoracic Surgery, Thorax, Chest, Respiration, Plos One, Journal de Chirurgie Thoracique et Cardio-vasculaire, Revue des Maladies Respiratoires

Sautès-Fridman C. Cancer Research, Frontiers in Immunology, European Journal of immunology, Journal of Immunology

Fridman WH. Nature, Cancer research, International Journal of Cancer, Nature Reviews Immunology...

Joubert PE. Autophagy journal.

Teillaud JL. Blood, Leukemia, FASEB J.; Cancer Res., Innate Immunity, J. Immunol.; European J. Immunol; J. Biol. Chem., Mol. Immunol.; J. Transl. Med.; Vaccine; PLoS ONE; J. Reprod. Immunol.; mAbs; Expert Rev Clin. Immunol.; Immunol. Letters; Protein Engineering, Design, and Selection (PEDS); ImmunoOncol.; Médecine/Sciences.

Dieu-Nosjean MC. Nature Review Immunol, Journal of Clinical Oncology, Blood, Journal of Immunology, BioMed Central, Journal of Leukocyte Biology, Cancers, Médecine et Sciences, Journal of Translational Medicine, Frontiers in Immunology.



Sibérel S. Scientific reports

#### **Equipe Complement and disease - V Frémeaux-Bacchi**

Dragon-Durey MA. American Journal of Kidney diseases, Journal of American Society of Nephrology, Plos One, E Biomedicine, International Journal of Environmental Research and Public Health, Pediatrics, Immunology and cell Biology, Journal of Immunological Methods, Molecular Immunology, Pediatric Nephrology.

Roumenina L. Blood, Kindey International, PLOS One, PLOS One, Scientific reports, Genes and Immunity, Lupus, Orphanet journal of rare diseases, Cellular & Molecular Immunology, Immunobiology, Clinical Kidney Journal, Tissue antigens and Clinical Pharmacology, BMC Gastroenterology; International Journal of Nephrology and Renovascular Disease, Coloids and Surfaces, Clinical and Experimental Immunology, Nano Letters.

Frémeaux-Bacchi V. JASN, Kidney International, Pediatric Nephrology, Blood, New England J Med, J Med Genet, Am J Transplantation, AJKD et Nephrology Dialysis Transplantation

#### **Évaluation de laboratoires (type Hceres)**

#### **Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud**

Cremer I. Membre du comité d'évaluation HCERES vague C (2016) pour l'évaluation des Ecoles Doctorales Sciences de la vie et de la santé ED462 et Sciences du mouvement humain ED62.

Damotte D. Membre du comité d'évaluation HCERES 2017 (évaluation CAC strasbourg)

#### **Évaluation de projets de recherche**

#### **Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud**

Cremer I. Expertise pour : Ligue contre le cancer, Cooperation ECOS - MINCyT (Argentine), AIRC (Association Italienne de Recherche contre le Cancer), Cancer Research UK, Cancéropôle Ile de France.

Damotte D. Cancéropôle grand est, Cancéropôle grand ouest

Sautès-Fridman C. ERC membre du panel LS7 (2016-2019), Institut National du cancer (INCa) 2010-2012, Vice presidente du comité PL-Bio, Austrian Fund, Wellcome Trust, Cancer Research UK, Science Foundation, Irelande

Fridman WH. ERC, Swiss Foundation for Cancer Research, Israeli Foundation for cancer Research etc...

Teillaud JL. Fondation ARSEP « Application for Research Grant & Associated Fellowship », INSERM (contrats d'interface hospitaliers - demande de prolongation), allocations post-doctorales 2016 - Cancéropôle Ile-de-France, Arthritis Fondation Courtin, MATWIN (Maturation and Accelerating Translation with Industry), Association Robert Debré pour la Recherche Médicale. Cancer Research UK (Royaume-Uni), Wellcome Trust (Royaume-Uni), Research Foundation Flanders (Fonds Wetenschappelijk Onderzoek - Vlaanderen, FWO) (Belgique), Fondation contre le Cancer / Stichting tegen Kanker (Belgique), Deutsche Forschungsgemeinschaft (Allemagne), Israel Science Foundation (ISF) (Israël), FONCyT (Fondo para la Investigación Científica y Tecnológica) (Argentine).

Dieu-Nosjean MC. Fondation ARC, DHOS INSERM, INCa, Ligue contre le Cancer, Association for International Cancer Research, Cariplo foundation, Ecos-Sud Argentina/Chili/Uruguay and France scientific cooperation, Czech SC. Foundation.

#### **Equipe Complement and disease - V Frémeaux-Bacchi**

Frémeaux-Bacchi V. SFNDT (2014-2017)

Dragon Durey MA. Cancéropôle Nord Ouest 2017

Roumenina L. The Netherlands Organisation for Health Research and Development, GCS MERRI MONTPELLIER-NIMES foundation, France, National Research, Development and Innovation Office, Hungary

### **3. Activités d'expertise scientifique**

*Team members consult for 19 different companies.*

#### **Activités de consultant**

**Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud**

Damotte D. Laboratoires pharmaceutiques (MSD, BMS, Roche, AstraZeneca)

Fridman WH. Novartis, Sanofi, LFB, Servier, Adaptimmune, Pierre Fabre Medicament, Curetech, Elsalys

Teillaud JL. Sanofi, Pfizer, Merck-Serono, Institut de Recherche Internationale Servier, Institut Pasteur et iDD Biotech

Dieu-Nosjean MC. BMS et Transgène

**Equipe Complement and disease - V Frémeaux-Bacchi**

Frémeaux-Bacchi V. Alexion Pharmaceuticals US and Fr

Dragon-Durey MA. Monitoring de l'essai INVAC-1 (Société INVECTYS), 2015-2017

Roumenina L. LFB, France

**Participation à des instances d'expertises (type Anses) ou de normalisation**

**Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud**

Marco Alifano. Membre du groupe d'experts « Trachéotomie » COMEDIM -APHP (2015)

**Expertise juridique**

**Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud**

Sautès-Fridman C. Présidente fondatrice du Groupement Européen d'Intérêt Economique (GEIE) ECI-EFIS

**4. Organisation de colloques / congrès**

*Team members contributed to the organization of 23 different international and national conferences.*

**Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud**

Alifano M. Congrès Annuel Generation Thorax, Nice 25-26 Mars 2016

Sautès-Fridman C. Symposium EFIS-EULAR « Basic and translational immunology » à Berlin, 25-29 Mai 2012: « B regulatory cells»; 3<sup>rd</sup> EFIS Summer school 2013 « Innovative therapies Based on Immunology », Paris, Centre de Recherche des Cordeliers, 12-13 Juillet; Symposium EFIS-EULAR« Basic and translational immunology » à Madrid, 13-16 Juin 2013, « Tertiary Lymphoid Structures in cancer and beyond »; Symposium EFIS-EULAR« Basic and translational immunology » à Paris, 11-14 Juin 2014, « Innate Lymphoid cells in health and disease »; Symposium EFIS-EULAR« Basic and translational immunology » à Rome, 2015: « Autoimmunity and inflammation, the price to pay for antibody therapies of cancer ? »; CRI-EATI, CIMT, AACR 1<sup>st</sup> Inaugural international Conference on immunotherapy, New York, 27-30 Septembre 2016, membre du comité d'organisation; 12<sup>ième</sup> Colloque Annuel du Cancéropole Immunothérapie des cancers : de la paille au traitement, 2016; Journées scientifiques annuelles du Département «Cancer, Immunologie et immunopathologie», CRC

Fridman WH. Colloque Annuel d'Immunothérapie Myltenyi aux Cordeliers, co-organisateur depuis 2012, Juillet, 500 participants; CRI-CIMT-EATI-AACR - The International Cancer Immunotherapy Conferences: Translating Science into Survival 'New York 2015, 2016 (1400 participants) Mainz 2017 ), Journées Immunité et cancer aux Cordeliers en janvier 2017, 400 participants)

Teillaud JL. Membre du comité d'organisation du Meeting annuel de la Société Française d'Immunologie (SFI), Paris, France, Novembre 4-7th, 2013; Membre du comité d'organisation du Meeting annuel de la Société Française d'Immunologie (SFI), Lille, France, Novembre 4-6th, 2014; Co-organisateur (avec les Dr. F. Perez et S. Moutel, Institut Curie, Paris) du meeting annuel du Groupement De Recherche (GDR) « Antibody and Therapeutic Targeting (ACCITH) » of CNRS, Institut Curie, Paris, France, November 12-13<sup>th</sup>, 2015.

Dieu-Nosjean MC. Co-organisatrice du Hay-day colloquium « Tertiary lymphoid system ». Cordeliers Research Center, Paris, France, February 22th, 2013.

**Equipe Complement and disease - V Frémeaux-Bacchi**

Roumenina L. 2016 Organization of the second meeting of the French Renal Endothelial club, Paris, France (2016), Complement master class - teaching course for students and researchers, Paris, France (2012-2014)

Frémeaux-Bacchi V. Club de la cellule endotheliale: 2016

## 5. Post-doctorants et chercheurs accueillis

Team members hosted 7 post docs or foreign reserachers for the last 5 years.

*On précisera ici les faits observables pertinents pour l'évaluation (nombre, publications, financements ...)*

### Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud

Cremer I. Jitka Fucikova (post-doctorante 2014-2015), financement Sotio Prague, 1 article as 1<sup>st</sup> author.

Damotte D. Jérôme Biton (post-doctorant 2012-2017) financement Medimmune, 1 article as 1<sup>st</sup> author submitted. Claudie Malanda (post-doctorante 2012-2017) financement Medimmune, 1 article as 1<sup>st</sup> author in preparation. Audrey Lupo (post-doctorante 2014-2017) 2 article as 1<sup>st</sup> author.

Dieu-Nosjean MC. Claire Germain (Post-doctorante 2012-2017), financement Medimmune, 3 articles as 1<sup>st</sup> author, 2 as 2<sup>sd</sup> author and 5 in other position; Myriam Lawand (2015-2017) financement INCa-PRTK puis MedImmune.

### Equipe Complement and disease - V Frémeaux-Bacchi

Roumenina L. Dennis Pedersen, Researcher form Department of Molecular Biology and Genetics, Center for Structural Biology, Aarhus University, Aarhus, Denmark, 3 months, publication: Pedersen, Roumenina et al., EMBO J, 2017

## 6. Interactions avec les acteurs socio-économiques

### Contrats de R&D avec des industriels

*The two teams are engaged in a strong partnerships with the industry in France and abroad with budget of >4,5 million euros for the last 5 years. The members of Cremer/Teillaud team work on translational projects with MedImmune (Damotte, Dieu-Nosjean), Sanofi (Teillaud) and clinical trials co-funded by BMS (Fridman and Sautes-Fridman). The members of Fremeaux-Bacchi team conduct projects funded by Alexion, Pierre Fabre and CSL Behring.*

### Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud

Damotte D. MedImmune AstraZeneca. Immune infiltrates in multiple NSCLC. 2016-2017, Responsable scientifique. 778 000 euros

Damotte D. MedImmune AstraZeneca. Impact of COPD on immune contexture in NSCLC. 2012-2017, Responsable scientifique. 1 608 000 euros

Sautès-Fridman C. Institut de Recherche Pierre Fabre, « Identification de cibles innovantes pour l'immunothérapie des cancers issues de l'analyse des profils immunologiques », 2015-2018 : PI 500 000 euros

Sautès-Fridman C. PRTK16 -GETUG-AFU-26 NIVOREN (etude cofinancée BMS) : role de la contexture immunitaire dans la réponse au nivolumab : 150 000 euros, 300 patients, responsable WP, 2016-2019

Sautès-Fridman C. BIONIKK: essai thérapeutique prospectif BMS avec anti-TKI et anti-ICP base sur la classification moléculaire et immunitaire des tumeurs (150 patients). 2017-2020. 350 000 euros, responsable scientifique

Teillaud JL. Sanofi. Antibody-based immunotherapy, 2016-2018, partenaire, 142 000 euros

Dieu-Nosjean MC. MedImmune AstraZeneca. Tertiary lymphoid structures in NSCLC. 2012-2017, Responsable scientifique. 1 608 000 euros

Dieu-Nosjean MC. MedImmune AstraZeneca. Tertiary lymphoid structures and Immune checkpoints in NSCLC. 2015-2017, Responsable scientifique. 257 000 euros.

### Equipe Complement and disease - V Frémeaux-Bacchi

Roumenina L. Pierre Fabre - industrial grant, partner, PI of a work package Complement and cancer, 407 000 Euros for this work package 2015-2018

Roumenina L. CSL Behring (industrial grant), PI, Hemopexin as an inhibitor of hemolysis-induced complement activation, 50 000 Euros, 2015-2018

**Bourses Cifre**

**Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud**

Teillaud JL. Sanofi financial support. 2016-2018. Beré Diallo (doctorante). Ab based immunotherapy.

**Créations de laboratoires communs avec une / des entreprise(s)**

Sans objet

**Création de réseaux ou d'unités mixtes technologiques**

Sans objet

**Créations d'entreprises, de start-up**

Sans objet

**7. Contrats de recherche financés par des institutions publiques ou caritatives**

The two teams are obtained prestigious public funding, including from the European commission (FP7 and H2020), CEFIPRA for French-Indian collaboration and from national funds, including ANR and INCa. Notable is the membership of the team Cremer/Teillaud in the LABEX Immuno-oncology and in the SIRIC Carpem. Funding from different foundations was also received, including ARC, CIT, AIRG and SFNDT. The international funding of the team Cremer/Teillaud was for ~70 K€ and for the team Fremeaux-Bacchi ~450 K€. The national funding was for ~2 500 K€ for the team Cremer/Teillaud and ~800 K€ for the team Fremeaux-Bacchi. Altogether, this makes a total budget for the 5 years of >3.2 million euros.

**Contrats européens (ERC, H2020, etc.) et internationaux (NSF, JSPS, NIH, Banque mondiale, FAO , etc.)**

**Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud**

Teillaud JL. H2020. Health - European HIV Vaccine Alliance, EHVA. 2016-2020. 70 000 euros (partenaire)

**Equipe Complement and disease - V Frémeaux-Bacchi**

Dragon-Durey MA. CEFIPRA CEFIPRA (Centre Franco-Indien pour la Promotion de La Recherche Avancée) 2012-2015 : Collaboration avec le Pr Arvind Bagga, du Pediatric Department of the All India Institute of Medical Sciences, New Delhi. Obtention d'une bourse doctorale+ frais de fonctionnement 150 000 euros

Dragon-Durey MA. CEFIPRA 2016-2018 : "International Collaboration on Anti-Factor H Autoantibody Associated Hemolytic Uremic Syndrome", Collaboration avec le Pr Arvind Bagga, New Delhi.

Frémeaux-Bacchi V. EURenOmics (FP7/2007-2013; under grant agreement no. 305608)-Partenaire., 400 000 euros

**Contrats nationaux (ANR, PHRC, FUI, INCA, etc.)**

**Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud**

Cremer I. INCa PL-BIO : Caractérisation phénotypique et fonctionnelle de souspopulations originales Natural Killer infiltrant les tumeurs solides humaines. Partenaire. 157 000€- 2012-2015

Cremer I. INCa PL-BIO : Impact of respiratory viral infections through TLR7 signaling on tumor progression and resistance to chemo- and immunotherapy in lung cancers. Principal Investigator. 326 000€. 2016-2019

Sautès-Fridman C. Contrat INCa 150 000 euros (resp équipe. Leader G Kroemer). 2010-2013

Sautès-Fridman C. PRTK16 -GETUG-AFU-26 NIVOREN : role de la contexture immunitaire dans la réponse au nivolumab 150 000 euros, 2016-2019

Sautès-Fridman C. Programme Carte d'Identité des Tumeurs de la Ligue Nationale contre le Cancer (CIT projet IRCC : Immune based biomarkers and relapse in RCC , 450 tumeurs) 350 00 euros, 2016-2019

Dieu-Nosjean MC. INCa PL-BIO: Influence du microenvironnement tumoral sur le recrutement et l'activité fonctionnelle des lymphocytes T dans les cancers du poumon, Partenaire. 145 000 euros, 2010-2014

Dieu-Nosjean MC. SIRIC CARPEM. Analyse du microenvironnement immunitaire dans les cancers. Partenaire. 40 000 euros. 2013-2017

Dieu-Nosjean MC. INCa. PRTK. Reconnaissance et contrôle des tumeurs par les lymphocytes Tgd : mécanismes et implications diagnostiques et immunothérapeutiques. Partenaire. 135 000 euros. 2014-2016

Dieu-Nosjean MC. INCa. PRTK. Association entre les structures lymphoïdes tertiaires, le profil mutationnel des tumeurs et l'immunité anti-tumorale : impact sur les thérapies ciblant les checkpoints immunitaires dans les cancers du poumon et du sein. Investigateur principal. 200 000 euros. 2017-2019

#### **Equipe Complement and disease - V Frémeaux-Bacchi**

Roumenina L. SIRIC-CARPEM Emerging projects, 50 000 Euros, PI, collaboration with Dr. Oliver Kepp; Role of the complement system in chemotherapy-induced immunogenic cancer cell death, 2013-2014

Roumenina L. Young researchers grant National research agency (ANR), PI, Mechanisms of complement-induced inflammation and endothelial cell damage in hemolytic conditions, 218 000 Euros, 2015-2018

Frémeaux-Bacchi V. INSERM transfert, Pep-C3, Principal investigateur (10 000 euros)

Frémeaux-Bacchi V. ANR 2016-2018-PI (COMPC3, 317 000 euros)

Frémeaux-Bacchi V. Kidneeds grands-PI 2016 (50 000 euros)

#### **Contrats avec les collectivités territoriales**

Sans objet

#### **Contrats financés dans le cadre du PIA**

##### **Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud**

**LaBex 2011-21 « Immuno-Oncologie » sous la coordination du Pr. G. Kroemer. Thème : Analyse du microenvironnement immunitaire dans les cancers. 40.000 Euros par an**

Sautès-Fridman C. 2012 à 2017 LabeX Immuno-oncology 40 000 euros/an (Coordonnatrice de l'Equipe 3)

Sautès-Fridman C. 2015-2016 CARPEM Etude du microenvironnement des tumeurs hépatiques humaines : relation avec les altérations génomiques (ImmunoCHC)(Col J. Zucmann-Rossi)

#### **Contrats financés par des associations caritatives et des fondations (ARC, FMR, FRM, etc.)**

##### **Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud**

Sautès-Fridman C. 2011 Contrat ARC/INCa/DIM Cancer pour achat BD pathway, coordinatrice (pour plateforme UMR\_S1138)(250 000 euros)

Sautès-Fridman C. 2016-2019. Programme Carte d'Identité des Tumeurs de la Ligue Nationale contre le Cancer (CIT projet IRCC : Immune based biomarkers and relapse in RCC )

Joubert PE. 2017-2019. ARC project foundation. Impact de la voie du métabolisme énergétique AMPK/mTOR sur l'effet pro-tumoral de TLR7 dans les cancers du poumon. 50 000 euros

Sibénil S. Fondation ARC (2013-2014). The vaccine effect of anti-CD20 mAbs : deciphering T-cell response. 50 000 euros

Dieu-Nosjean MC. Fondation ARC (2011-2014) Identification de nouvelles cibles thérapeutiques reconnues par les anticorps sécrétés localement et valeur pronostique des lymphocytes B intra-tumoraux dans les cancers pulmonaires. 300 000 euros.

#### **Equipe Complement and disease - V Frémeaux-Bacchi**

Roumenina L. 2013-2015 French Nephrology society - 2x one year salary for a medical doctor to perform research in the group, supervisor

Roumenina L. 2015-2016 ARC Establishment of young teams, 50 000 Euros, PI, Role of complement in cancer development and chemotherapy

Frémeaux-Bacchi V. Bourses de recherche de l'association AIRG (2012-2014) pour le développement des connaissances sur le SHU atypique ;

## 8. Indices de reconnaissance

*Prestigious awards were received, including for investment in research (Cremer, Dieu-Nosjean), from Kidney foundation (Frémeaux-Bacchi) and from CRC (Siberil). Prof. Fridman holds The Legion of Honor and Coley awards. The members of the two teams received 98 invitations for presentations at conferences and seminars at international and national level, of the 61 in the team Cremer/Teillaud and 37 in the team Frémeaux-Bacchi. Researchers of the teams have responsibilities in 16 different scientific organizations.*

*On s'en tiendra aux indices de reconnaissance les plus significatifs pour le rayonnement et l'attractivité de l'unité de recherche.*

### Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud

Fridman WH. Président du Cancéropole Ile de France

Fridman WH. Directeur Adjoint du **CARPEM** (CAncer Research for PErsonalized Medicine) : **Site de Recherche Intégrée sur le Cancer** de l'AP-HP regroupant les hôpitaux universitaires suivants : Hôpital Européen Georges Pompidou, Hôpital Cochin/Hôtel-Dieu et le département d'hématologie de l'hôpital Necker

### Prix

### Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud

Fridman WH. Lauréat du Prix W.B. Coley, New York 2010

Sibérel S. Prix Jeunes chercheurs des Cordeliers 2015 (40 000 euros) pour un projet en collaboration avec Equipe 11 du CRC)

### Equipe Complement and disease - V Frémeaux-Bacchi

Frémeaux-Bacchi V. Prix de la Fondation du rein (2012), Professeur associé de la Faculté de Médecine de Necker Enfants Malades (2016 septembre)

### Distinctions

### Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud

Cremer I. Prime d'investissement recherche (PIR), UPMC 2012-2016, Prime de direction d'Ecole Doctorale, UPMC, depuis 2012

Fridman WH. Chevalier de l'Ordre National du Mérite, Chevalier de l'ordre National de la légion d'Honneur

Dieu-Nosjean MC. 2014-2017 : Prime d'Encadrement Doctoral et de Recherche (PEDR) INSERM

### Responsabilités dans des sociétés savantes

### Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud

Sautès-Fridman C. Présidente de l'European Federation of Immunology Societies (EFIS) 2009-2012

Sautès-Fridman C. Past-Présidente de l'European Federation of Immunology Societies (EFIS) 2012-2015

Sautès-Fridman C. Member of the « Scientific Panel for Health », Expert group (23 members) nominated by the European Commission, in charge of perspective and innovation in medicine 2015-2021

Sautès-Fridman C. Chargée de la communication à l'European Academy of Tumor Immunology (EATI)

Fridman WH. Vice-Président de l'European Academy of Tumor Immunology (EATI)

Fridman WH. Membre de l'Académie Europaea

Teillaud JL. Membre du Conseil d'Administration de la Société Française d'Immunologie (SFI) (2011-2014), trésorier de la Société Française d'Immunologie (SFI) (2011-2014)

Teillaud JL. Membre de « The Antibody Society » (depuis sa création en 2010)

**Equipe Complement and disease - V Frémeaux-Bacchi**

Dragon-Durey MA. Présidente de la collégiale d'Immunologie de l'APHP 2014-2016, membre depuis 2006.

Dragon-Durey MA. Participation au travail avec la DGOS pour la mise en place des nouvelles nomenclatures des actes de biologie médicale pour l'Immunologie humorale (depuis 2013)

Dragon-Durey MA. Membre de la sous-collégiale d'Autoimmunité (depuis 2000)

Dragon-Durey MA. Membre de l'ASSIM (association des collègues des enseignants d'Immunologie des universités de langue française) (depuis 2006)

Dragon-Durey MA. Membre de l'EASI group (European Autoimmunity Standardization Initiative) (depuis 2015)

Dragon-Durey MA. Membre de Expert Meeting on Standardization of Complement Measurements (depuis 2016)

Dragon-Durey MA. Membre du "European Working Party on the Genetics of HUS and MPGN" (depuis 2005)

Frémeaux-Bacchi V. Présidente de la Commission Recherche de la Société Francophone de Néphrologie, Dialyse et Transplantation (2014-2018)

Roumenina L. Member of the ethical committee for animal experimentation N5 Charles Darwin

**Invitations à des colloques / congrès à l'étranger, séjours dans des laboratoires étrangers**

**Equipe Cancer, Immune Control and Escape - I Cremer/JL Teillaud**

Alifano M. Reste-t-il une place pour la médiastinoscopie ? Société d'Imagerie Thoracique, 29 juin 2012.

Alifano M. Y-a-t-il une place pour les études randomisées en chirurgie ? (Modérateur). 4e Congrès de Génération Thorax, Paris, 30-31 Mars 2012.

Alifano M. Marqueurs cellulaires et moléculaires du cancer du poumon pour les nuls (Modérateur), Société Française de Chirurgie Thoracique et cardiovasculaire. Nice, 30 Mai-2 Juin 2012.

Alifano M. La plèvre confiée au chirurgien : fistules pleurales. 17e congrès de pneumologie de langue française. Lille 1-3 Février 2013.

Alifano M. Chirurgie des nodules en verre dépoli: ce que le chirurgien attend de l'imagerie. Journée de Radiologie Thoracique de la SFR. Paris, 15 Juillet 2013

Alifano M. Traitement chirurgical du cancer pulmonaire. Session CanceroNurses AFITCH-OR. 24<sup>th</sup> International Congress on Anti-Cancer Treatment (ICACT), Paris, February 5-7 2013.

Alifano M. Session Cas cliniques: Modérateurs. Congrès Génération Thorax. Paris, 23 Mars 2013.

Alifano M. Les fuites aériennes après résection pulmonaire. Réunion du Groupe Thorax. Pontoise, 18 Mai 2013

Alifano M. Session : Prise en charge globale du cancer pulmonaire : Président. 18e congrès de pneumologie de langue française. Marseille 31 Janvier-2 Février 2014.

Alifano M. Les sténoses laryngo-trachéales idiopathiques. Congrès annuel de la Société de Chirurgie Thoracique et Cardiovasculaire, 11-14 Juin 2014, Tours, France.

Alifano M. Thoracoscopy and mediastinoscopy revisited. Care for the COPD-Asthma patients. An Interactive clinical course. February 4-7, Paris

Alifano M. Pneumotorace nella donna: aspetti clinic-patologici. Catania, Italie, 19-20 Juin 2015.

Alifano M. Endométriose extra-pelvienne. Congrès : L'endométriologie à travers les âges de la vie. Liège, Belgique, 7 Mars 2015.

Alifano M. Surgery for Thoracic Endometriosis. International Congress on Endometriosis. Kolkata, India 20-22 Novembre 2015

Alifano M. Participant of the Faculty: Italian Experience on VATS lobectomy: First Consensus Conference. 29-30 Octobre 2015, Giulianova Lido, Italie

Alifano M. Criticità ed Esperienze a Confronto- Protocolli ERAS. L'esperienza Francese. INCONTRO VATS GROUP: E.R.A.S. IN CHIRURGIA TORACICA, Genova, Italie, 23 Janvier 2016

Alifano M. Cancer pulmonaire : la maladie, l'hôte, les traitements Etat des lieux et évolution. 8<sup>ème</sup> Congrès Génération thorax : 25 et 26 mars 2016, Nice, France

Alifano M. Update in chirurgia coloretale, endometriosi e patologia Funzionale Colica, I CONGRESSO SPIGC LOMBARDIA. 12 avril 2016, Brescia, Italie

Alifano M. Conférences dans le cadre de la mission du 09 au 14 mai 2016 à Shanghai First People Hospital, CHINE

Alifano M. Tumor immune microenvironment in NSCLC : which future perspectives? 16 juin 2016 Reggio Emilia, Italie.

Alifano M. La patologia toracica di interesse chirurgico e medico : le convergenze parallele. 8 novembre 2016 Verona, Italie.

Alifano M. Trattamento Chirurgico del cancro del polmone oligometastatico. Padova, Italie, Thoracic Oncology Padova, Annual Meeting 31 Mars, 1 Avril 2017.

Sautès-Fridman C. 10th EFIS-EJI Tatra Immunology Conference, Molecular Determinants of T Cell Immunity, Štrbské Pleso (Tatra Mountains), Slovakia, June 9 - 13, 2012

Sautès-Fridman C. CITIM, Cracovie Avril 2013, 3<sup>rd</sup> Cancer Immunotherapy and Immunomonitoring meeting, Cracovie, 27-29 Avril "Role of Tertiary Lymphoid Structures in the anti-tumor response"

Sautès-Fridman C. Keystone Symposia à SnowBird - USA, 2014

Sautès-Fridman C. CITIM, Ljubljana Avril 2014, "TLS as conductors of the intratumoral immune response"

Sautès-Fridman C. Société Soteo, Prague, 16 Mai, "The two faces of the tumor microenvironment in human cancers"

Sautès-Fridman C. Société Tunisienne d'Immunologie, 12<sup>èmes</sup> Journées Scientifiques, 16 - 18 Octobre 2014, Hôtel Le Royal, Yasmine Hammamet

Sautès-Fridman C. Ruggero Ceppellini Conference, Naples, 12 Septembre, "The immune contexture of primary and metastatic human tumors"

Sautès-Fridman C. 2nd International Molecular Immunology & Immunogenetics Congress" (MIMIC-II), April 27-30, 2014 Antalya, "The immune contexture of primary and metastatic human tumors"

Sautès-Fridman C. 7th International Conference on Tumor Microenvironment: Progression, Therapy & Prevention Tel Aviv, Israel, October 11-15, 2015, "TLS as conductors of the intratumoral immune response"

Sautès-Fridman C. National Taiwan University in Taipei, Yonglin Healthcare Symposium series, 2016

Sautès-Fridman C. CITIM Prague Avril 2016

Sautès-Fridman C. Villa Vigoni, Cours "cell death in Neurodegeneration and Cancer", Juin 2016

Fridman WH. Orateur invité dans de nombreux congrès internationaux (80 invitations sur la période) dont :

Fridman WH Euro Asian experts Conf on Immune Biomarkers for Personalized Medicine In Oncology à Shanghai , 2013

Fridman WH AACR meeting Washington, Avril 2013,

Fridman WH AACR meeting San Diego, Avril 2014

Fridman WH Keystone Symposia à SnowBird - USA, 2014

Fridman WH CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival New York Septembre 2015 et 2016

Fridman WH Princess Takamatsu Cancer Research Fund Symposium à Tokyo, Nov 2014

Fridman WH ECCO - ESMO European Cancer Congress in Vienna, Septembre 2014

Fridman WH Congres de la FASEB, Steam Boat Spring, Colorado, Juin 2015

Fridman WH National Taiwan University in Taipei, Yonglin Healthcare Symposium series, 2016

Fridman WH Annual Meeting of Korean Association for Clinical Oncology, in Seoul, Mai 2016

Teillaud JL. séjours dans le laboratoire du Prof. J. Mordoh (Centro de Investigaciones Oncológicas-Fundación Cáncer - FUCA), Buenos Aires, Argentina, 15 days twice a year since 2014

Teillaud JL. 10<sup>èmes</sup> Journées Thématiques des Pharmaciens Hospitaliers, Montreux, Swiss, 2014/05



Teillaud JL. (invitation: plenary session), “The Janus face of anti-CD20 antibody: from tumor killing to vaccinal effect”, II<sup>d</sup> French-Argentinian Immunology Meeting (FAIC2015) -LASID, Buenos Aires, Argentina 2015/11

Teillaud JL. (invitation: plenary session), “Therapeutic antibodies for cancer treatment: from Fc optimization to vaccinal effect”, Israel-France Symposium « Immunology, Cancer and Ageing », Tel-Aviv, Israel, 2016/03

Teillaud JL. (invitation: plenary session). « The vaccinal effect of monoclonal antibodies in cancer therapy: the anti-CD20 case », 12th International Workshop Immunotherapy 2016 « Mapping the road for a long lasting immune-mediated control of cancer », La Habana, Cuba, 2016/10

Dieu-Nosjean MC. (invitation: plenary session) Tertiary lymphoid structures in lung cancer patients: a major contributor to a beneficial immune microenvironment. Miltenyi Biotec EATI and SITC meeting « Natural and therapy-induced anticancer immunosurveillance : the immunoscore », Paris, 2014/07

Dieu-Nosjean MC. (invitation: plenary session) Tertiary lymphoid structures, as a new driver of a protective immune response in human lung cancer. Program ADELH international congress, Paris, France, 2014/10

Dieu-Nosjean MC. (invitation: plenary session) Role of Tertiary lymphoid structures in the shaping of an efficient and beneficial immune reaction in lung cancer patients, 4<sup>th</sup> World Congress on « Cancer Science and Therapy », Chicago, USA, 2014/10

Dieu-Nosjean MC. (invitation: plenary session), Tertiary lymphoid structure-associated B cells are key players in anti-tumor immunity. « Therapeutic antibodies 2015: new trends in Oncology ». Groupement De Recherche (GDR) Antibody and Therapeutic Targeting (ACCITH) of CNRS, Institut Curie, Paris, France, 2015/11

Dieu-Nosjean MC. (invitation: plenary session), « Induction of Tertiary Lymphoid Structures, a new strategy of the immune system to fight against tumor », Symposium Crowbio, Paris, France, 2016/06

Dieu-Nosjean MC. (invitation: plenary session), « Tumor-associated tertiary lymphoid structures: a major contributor to a protective immune response ». 9th Canadian Cancer Immunotherapy Consortium (CCIC) Symposium, Halifax, Canada, 2016/06

Dieu-Nosjean MC. (invitation: plenary session), « Emergence of Tertiary Lymphoid Structures as a first line of defense against tumors », New Immuno-Oncology Event « Give life a chance through Cancer Immunotherapy », Budapest, Hungary, 2016/09

Dieu-Nosjean MC. (invitation: plenary session). « Induction of Tertiary Lymphoid Structures, a new strategy of the immune system to fight against tumor », 12th International Workshop Immunotherapy 2016 « Mapping the road for a long lasting immune-mediated control of cancer », La Habana, Cuba, 2016/10

Dieu-Nosjean MC. (invitation plenary session) « Tertiary lymphoid structures as conductors of the intratumoral immune response », 12<sup>e</sup> colloque annuel « Cancer Immunotherapy: from bench to bedside », Cancéropôle Ile-de-France, Paris, France, 2016/11

Dieu-Nosjean MC. (invitation: plenary session), « Les structures lymphoïdes tertiaires dans le monde de la cancérologie », 4<sup>ème</sup> édition ImmunoSem et Bristol-Myers Squibb, Paris, France, 2016/11

Sibérl S. Invited speaker, Mastering Immunity Congress (Proimmune), “Analysis of peripheral T-cell compartments in high-grade Follicular Lymphoma patients treated with rituximab-based regimens”, Oxford 2017, March 23-24

#### **Equipe Complement and disease - V Frémeaux-Bacchi**

Roumenina L. **Invited speaker, chairperson** Hemolysis drives particular susceptibility of glomerular endothelium to complement overactivation, 10th International Conference on Complement Therapeutics, Heraklion, Greece, 24-29/06/2017

Roumenina L. **Invited speaker**, Complement system for clinicians: molecular mechanism of activation and regulation, 20<sup>th</sup> congress on immune pathologies and rare diseases, Torino, Italy, 25-28/01 2017

Roumenina L. **Invited speaker, chairperson** Understanding complement-mediated renal diseases using structure-function relationships, Aegean Conference on Complement Therapeutics, Rhodes, Greece, 28/06-03/07/2016

Roumenina L. **Invited speaker**, Role of the complement system in the immune response - relevance for drug development, Assessment of immune response in toxicology conference, Giverny, France, 26-27/05 2016

Roumenina L. **Invited speaker, chairperson** Update on primary complement deficiencies, 2<sup>nd</sup> J project congress on Immune deficiencies, Antalya, Turkey, 02-05/03 2016

Roumenina L. **Invited lecture** Complement and hemolysis, University Hospital of Zurich, Zurich, Switzerland, 2015

Roumenina L. **Invited lecture** Understanding complement mediated diseases using patients' mutations and protein structure-function relationships, CSL Behring, Bern, Switzerland, 2015

Roumenina L. **Invited speaker** aHUS and related disorders meeting, Innsbruck, Austria, 2015

Roumenina L. **Invited lecture** Heme as a modulator of the complement activation, Department of Molecular Biology and Genetics Aarhus University Gustav Wiedsvej, 2013

Roumenina L. **Invited speaker, member of the best presentation award jury** A prevalent reverse hybrid CFHR1/FH gene in aHUS patients induces deregulation of the alternative pathway, 14th European Meeting on Complement in Human Disease, Jena, Germany, 2013

Dragon-Durey MA. Complement in glomerulopathies. IX Annual training course on pediatric nephrology (New Delhi, 1-2 April 2017)

Dragon-Durey MA. Complement biology in kidney disease. IPNA AsPNA Junior Class, New Delhi, All India Institute of Medical Sciences, April 2016

Dragon-Durey MA. Autoantibody mediated HUS, XII<sup>nd</sup> Asian Congress of pediatric Nephrology, New Delhi, India, Dec 2014.

Dragon-Durey MA. Historical and physiopathological aspects of AI-HUS. 1<sup>st</sup> Workshop on anti-FH autoantibodies. Paris, May 2014

Dragon-Durey MA. Complement system and HUS in Seminar on Complement Disorders and the Kidney. All India Institute of Medical Sciences, New Delhi, March 2013

Dragon-Durey MA. Anti-factor H autoantibodies associated with atypical HUS or C3 glomerulopathy : What is common and what is different? 8<sup>th</sup> International Congress of Auto-immunity, Granada, May 2012

Frémeaux-Bacchi V. Monoclonal Gammopathy-associated TMA, New Orleans 3<sup>th</sup> IKMG meeting (international)

Frémeaux-Bacchi V. Biology of atypical HUS ; 17<sup>th</sup> IPNA, Iguacu (international)

Frémeaux-Bacchi V. Quoi de neuf dans la physiopathologie des GC3? Société de Néphrologie (national)

Frémeaux-Bacchi V. Complement and ANCA -associated Vasculitis : from murine model to clinical trial; 17<sup>th</sup> international Vasculitis, London (international)

Frémeaux-Bacchi V. Update on acquired factors, C3G Focus Group Meeting, Uppsala, Sweden (international)

Frémeaux-Bacchi V. From mutations in Complement genes to clinical use of Eculizumab; 52<sup>th</sup> congress ERA-EDTA, London (international)

Frémeaux-Bacchi V. La Biologie du SHU atypique en 2014, Société de Néphrologie Pédiatrique (national)

Frémeaux-Bacchi V. *Complément et lupus : comment explorer ? Journées Antill Guyanne* (national)

Frémeaux-Bacchi V. **Complement Abnormalities in Atypical Hemolytic Uremic Syndrome and in C3 glomerulopathy; Reunions Franco Suisse, France** (national)

Frémeaux-Bacchi V. Complement Abnormalities in Atypical Hemolytic Uremic Syndrome and in C3 glomerulopathy, Starsbourg (national)

Frémeaux-Bacchi V. Complement in C3G, La Rochelle, IKMG meeting (national)

Frémeaux-Bacchi V. Complement and Diseases ; Master Class HTA (international)

Frémeaux-Bacchi V. Mutations HUS, DGKE; Actualites Néphrologiques (national)

Frémeaux-Bacchi V. Complement Abnormalities in Atypical Hemolytic Uremic Syndrome and in C3 glomerulopathy, Novartis, Basel. (international)

Frémeaux-Bacchi V. Anomalies génétiques du complément dans les maladies glomérulaires ; Société de Biologie (national)

Frémeaux-Bacchi V. Syndrome hémolytique et urémique: Du gène à la maladie ; Journée mondiale du rein, (national)

Frémeaux-Bacchi V. The genetics of C3 glomerulopathy; Société de Néphrologie, Nantes (national)

Frémeaux-Bacchi V. **Identification d'un nouveau gène dans le SHU atypique ; Société de Néphrologie, Nantes** (national)